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Pre-eclampsia is a pregnancy-specific disorder affecting 2-8% of all pregnancies. Every year 
approximately 70 000 women die due to pre-eclampsia and its complications. It accounts for
nearly one fifth of all maternal deaths. The only treatment for pre-eclampsia is delivery, 
which may lead to a premature birth. The aim of this study was to find ways to predict pre-
eclampsia and test the performance of low dose aspirin in the prevention of pre-eclampsia in 
women at high risk.
This thesis includes data from two study cohorts. Participants of Study I comprise 21 
nulliparous, pre-eclamptic women and 11 normotensive, non-proteinuric women recruited 
between January 1996 to February 1998 in the maternity clinics, the prenatal clinic and the 
antenatal ward of Helsinki University Central Hospital. The participants of Studies II-V
consist of 947 pregnant women with and 117 without known risk factors for pre-eclampsia
who were included in the PREDO project between September 2005 and December 2009 from
12+0 to 13+6 weeks of gestation in 1 of the 10 participating hospital maternity clinics.
To study the role of different combinations of risk factors in predicting pre-eclampsia, we 
studied 903 women using cluster analysis (Study IV). Of these, 86 (9.5%) developed pre-
eclampsia, 10 (11.6%) had early-onset disease and 36 (41.9%) had severe disease. Women 
who have had pre-eclampsia, or small for gestational age (SGA) newborn in an earlier 
pregnancy, or who have chronic hypertension (CHT) or type 1 diabetes mellitus were at
highest risk of early-onset pre-eclampsia, severe pre-eclampia and preterm pre-eclampsia. 
Pre-eclampsia in a previous pregnancy and a body mass index over 30 kg/m2 were the most 
important risk factors for term pre-eclampsia. Early-onset and late-onset pre-eclampsia had
different risk profiles.  Moreover, the risk of pre-eclampsia increased exponentially with 
respect to the number of risk factors. 
To assess the role of vasoactive agents in the prediction of pre-eclampsia, we studied
placental growth factor (PlGF) and soluble vascular endothelial growth factor receptor-1
(VEGF-1 or sFlt-1) and their ratio, at 12-14, 18-20 and 26-28 weeks of gestation in a total of
53 women at high risk for pre-eclampsia and healthy controls (Study III). Of these, 27 
developed pre-eclampsia: 6 early-onset and 21 late-onset forms of the disease. By the second 
measurement, differences in PlGF concentrations, and by the third measurement, differences 
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in sFlt-1 concentrations were discovered between those who developed early-onset pre-
eclampsia and others. With a cut-off point of 40 the ratio of sFlt-1/PlGF identified all women 
who developed early-onset pre-eclampsia, with no false positives, 4 to 6 weeks before the 
clinical diagnosis. 
To study the predisposing factors to superimposed pre-eclampsia in women with CHT (Study 
V) we assessed markers of placental and endothelial function, and maternal cardiac function, 
and renal tubular injury at all three timepoints in women with CHT (n=90) and healthy 
controls (n=90). Superimposed pre-eclampsia was diagnosed in women with CHT with new 
proteinuria over 0.3g per day after 20+0 weeks of gestation. In women who subsequently 
developed superimposed pre-eclampsia, plasma syndecan-1 concentrations were lower at 
26+0-27+6 weeks (p=0.03) and plasma PlGF concentrations were lower (p=0.002) across 
gestation, compared to women with CHT without superimposed pre-eclampsia. Urine 
albumin creatine ratio (ACR) was elevated across gestation in women with CHT who 
subsequently developed superimposed pre-eclampsia compared with women with CHT only 
(p=0.007) or healthy controls (p=0.002). At the first timepoint receiver operator curve (ROC) 
value for ACR for prediction of pre-eclampsia was 0.87 (CI 0.73-1.0).
We investigated the concentrations of total and individual free fatty acids (FFA) in pre-
eclamptic and normotensive pregnant women and the relationship between FFA 
concentrations and insulin sensitivity (Study I). Total FFA concentrations at baseline were 
67% higher in pre-eclamptic than normotensive pregnancies (P = 0.0002). This difference 
was no longer significant after an oral glucose load. At the baseline, the differences between 
pre-eclamptic and normotensive pregnancies were largest in the concentrations of the oleic 
(75%), linoleic (129%) and arachidonic (315%) acids. 
In the aspirin trial (Study II), we randomised 152 women with risk factors for pre-eclampsia 
and abnormal uterine artery flow upon Doppler velocimetry to low dose aspirin (100 mg per 
day) or placebo. We could not demonstrate any differences in the primary or secondary 
outcomes. Because the number of women identified as high risk by ultrasound was lower than 
expected, we concluded a meta-analysis of placebo-controlled aspirin trials with women 
whose uterine artery measurement indicated a high risk. According to the meta-analysis (3 
trials, 346 women) low dose aspirin started at or before 16 weeks of gestation reduced the risk 
of pre-eclampsia (Risk ratio (RR) 0.6, 95% confidence interval (CI) 0.37-0.83), and severe 
pre-eclampsia (RR 0.3, 95%CI 0.11-0.69). 
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In conclusion, the risk of pre-eclampsia increased exponentially with respect to the number of 
risk factors. The sFlt-1/PlGF ratio identified women who develop early-onset pre-eclampsia 
weeks before the onset of clinical findings. The association between ACR in early pregnancy 
and superimposed pre-eclampsia is an evidence that pre-existing endothelial dysfunction in 
women with CHT may contribute to development of pre-eclampsia. It may be used in the 
prediction of pre-eclampsia in women with CHT already at the 12 weeks of gestation.
Reduced syndecan-1 and PlGF antedate the development of pre-eclampsia in women with 
CHT, which implicate endothelial glycocalyx disturbance and reduced angiogenic capacity in 
the pathophysiology of superimposed pre-eclampsia. Women with established pre-eclampsia
had higher FFA concentrations, which may influence several characteristics of pre-eclampsia, 
for example increased insulin resistance, endothelial cell dysfunction and altered production 
of vasoactive substances. According to the meta-analysis, low dose aspirin reduced the risk of 
pre-eclampsia and severe pre-eclampsia in women with abnormal uterine artery flow.
Consequently, low dose aspirin at a dose of 100 mg per day should be recommended to 
initiate before the 16th week of gestation in high-risk women and continued until 35+0 weeks 
of gestation.
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INTRODUCTION
Pre-eclampsia affects 2-8% of all pregnancies worldwide (1). In Finland, 2.5% of babies are 
born from pre-eclamptic pregnancies, similar rates have been reported in other Nordic 
countries (2,3). Pre-eclampsia is a pregnancy-specific condition currently defined as blood 
pressure above 140 mmHg systolic and/or 90 mmHg diastolic and proteinuria over 0.3mg per 
day after 20+0 weeks of gestation (4) and may include a wide range of other symptoms and 
findings. Pre-eclampsia and its consequences are important causes of both maternal and 
newborn morbidity and mortality. The risks are not only restricted in the period of pregnancy, 
but long-term maternal risks after pre-eclampsia include chronic hypertension, stroke, and 
ischemic heart disease (5,6). Children and adults born from pre-eclamptic pregnancies have 
elevated risks of long-term cardiovascular (7,8) and mental health disorders and cognitive 
impairments (9,10).
Pre-eclampsia is a multi-systemic syndrome. The aetiology of pre-eclampsia is still largely 
unknown, but we know more regarding the pathogenesis. The defects in placentation, which 
later lead to clinical pre-eclampsia, already emerge in the early weeks of gestation. In pre-
eclampsia, the remodelling of placental spiral arteries is incomplete. The cytotrophoblast 
invasion of decidua is shallow, limited in the superficial decidua and the myometrial 
segments of the spiral arteries remain narrow and high-resistance (11-13). This first stage in 
the pathogenesis of pre-eclampsia, poor placentation, is followed by the second stage 
involving endothelial damage. The symptoms of pre-eclampsia reflect this endothelial 
dysfunction, which is induced by antiangiogenic factors, systemic inflammation, 
immunologic factors, and hypoxia, which all contribute to the development of this 
heterogenous condition (13). The result is vasoconstriction, end-organ ischaemia and 
increased vascular permeability (14).
An imbalance of the angiogenic factors plays a crucial role in the pathogenesis of pre-
eclampsia (15). Vascular endothelial growth factor (VEGF) is necessary for glomerular 
capillary repair and in maintaining the health of the endothelium (13). Placental growth factor 
(PlGF) is a potent angiogenic growth factor and has a structural homology to VEGF-A.
VEGF and PlGF have a common receptor, VEGF receptor-1, also called fms-like tyrosine 
kinase (Flt-1) on endothelial cells. Its soluble variant, sFlt-1, binds both PlGF and VEGF, and 
inhibits their binding to endothelial cell surface receptors. In pre-eclamptic women,
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expression of sFlt-1 is upregulated (15) and an increase in serum sFlt-1 seems to precede 
clinical syndrome (16-18).
Metabolic characteristics of pre-eclampsia include reduced glucose utilisation, 
hyperinsulinemia and hyperlipidemia (19,20) and many other known cardiovascular risk 
factors (21-24). High plasma lipids may contribute to the development of pre-eclampsia by 
increasing vascular dysfunction in uteroplacental circulation by advancing lipid changes in 
the walls of already poorly transformed spiral arteries (25).
Superimposed pre-eclampsia is diagnosed in a pregnant woman with chronic hypertension 
(CHT) when she develops new-onset proteinuria over 0.3g per day after 20+0 weeks of 
gestation. Approximately 26% of women with CHT develop superimposed pre-eclampsia 
(26). Endothelial dysfunction and abnormalities in cardiac and renal function are proposed to 
contribute to the development of superimposed pre-eclampsia in women with CHT.
A great effort regarding finding tools to predict pre-eclampsia before the clinical onset of the 
disease has been made. Demographic factors, biochemical markers, or biophysical findings 
may offer clinical tools in the prediction. An ideal biochemical marker plays a central role in 
pathogenesis, is present early on or before the clinical manifestations, is easy and inexpensive
to test for, shows a high sensitivity and specificity for the disease, correlates with the severity 
of the disease, and is non-detectable or present at low levels in normal pregnancies (27).
There is strong evidence that low dose aspirin would prevent pre-eclampsia. Aspirin’s 
preventive function is thought to be due to its favourable effect on prostaglandin production, 
particularly the prostacyclin-thromboxane ratio, which is in imbalance in pre-eclamptic 
women before the clinical disease. Other possible routes of the action of low dose aspirin are




Pre-eclampsia is a pregnancy-specific disorder, affecting 2-8% of all pregnancies (1). It is one 
of the greatest challenges of obstetrics causing nearly one-fifth of all maternal deaths (28,29)
and increasing the risk of adverse outcomes. Pre-eclampsia is a placental disease and 
symptoms arise from endothelial dysfunction. It is characterised by increased blood pressure 
and proteinuria, and a broad spectrum of other symptoms. These include headache, visual 
disturbances, oedema, upper abdominal pain, nausea, and may lead to serious complications,
and even death of the mother or fetus. Placental dysfunction may affect fetal growth and 
wellbeing. At one end of the spectrum is pre-eclampsia with mild symptoms in a term 
pregnancy, and at the other end is rapidly progressing early-onset pre-eclampsia with severe,
even life threatening, symptoms. The only treatment of pre-eclampsia is delivery, which may 
lead to a very premature birth. 
Symptoms typical in pre-eclampsia were mentioned as early as in ancient Greek sources 
originating from the time before Hippocrates (30). The Coan Prognosis depicted: “In 
pregnancy, the drowsy headaches with heaviness is bad; such cases are perhaps liable to some 
sort of fits at the same time” (31). For thousands of years, the disease was known as a 
convulsive disease of pregnancy and different theories explaining the reasons changed over
times (30). In a symposium on eclampsia, held in Giessen in 1901, it was agreed upon that the
disease was caused by a toxin. This was followed by several hypotheses on the source of the 
toxin. The theory was later refuted. However, today we still use the word toxaemia when 
referring to pre-eclampsia.  
Definitions
Definitions of pre-eclampsia have varied throughout the times. Improved understanding of the 
pathogenesis of pre-eclampsia has influenced the definitions. Pre-eclampsia is a pregnancy 
specific condition diagnosed when blood pressure is elevated above 140 mmHg systolic 
and/or 90 mmHg diastolic and proteinuria over 0.3 mg per day after 20+0 weeks of gestation
(4). Severe pre-eclampsia is diagnosed when blood pressure exceeds 160 mmHg systolic 
and/or 110 mmHg diastolic or proteinuria is over 5 g per day. Superimposed pre-eclampsia is 
diagnosed when a pregnant woman with CHT has new-onset proteinuria over 0.3 mg per day 
after 20+0 weeks of gestation. When blood pressure is elevated after 20+0 weeks of gestation 
without proteinuria, the condition is defined as gestational hypertension. Pre-eclampsia is 
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commonly divided into early- and late-onset disease and preterm and term subtypes based on 
the time of delivery or time of the diagnosis (Table 1). 
Table 1. Definitions of pre-eclampsia
Pre-eclampsia
+0 weeks of gestation and 
Early-onset
Late-onset
Delivery (or diagnosis) before 34+0 weeks of gestation
Delivery at or after 34+0 weeks of gestation
Preterm 
Term 
Delivery (or diagnosis) before 37+0 weeks of gestation
Delivery at or after 37+0 weeks of gestation
Severe 
Eclampsia New-onset grand mal seizures in a woman with pre-
eclampsia
Gestational hypertension mHg or diastolic blood 
the 20th week of gestation without 
proteinuria
Chronic hypertension
+0 weeks of gestation without 
proteinuria
Superimposed pre-eclampsia New proteinuria over 0.3 g/day after 20+0 weeks of gestation
in a pregnant woman with chronic hypertension
Recently, pre-eclampsia definitions have been updated. The American College of 
Obstetricians and Gynecologists (ACOG) proposed, in the Task Force on Hypertension in 
gestation (32) recommendations that, in the absence of proteinuria, pre-eclampsia could be 
diagnosed when newly diagnosed hypertension occurs in association with thrombocytopenia, 
impaired liver function, new development of renal insufficiency, pulmonary oedema, or new-
onset cerebral or visual disturbances. The Australasian Society for the Study of Hypertension 
and the Society of Obstetricians and Gynaecologists of Canada have adopted even broader 
definitions and include fetal features, such as fetal growth restriction, in the definitions.
ACOG suggested that massive proteinuria (greater than 5g) should be removed from the 
definition of severe pre-eclampsia, and recommends that any one of the following findings 
indicate severe form of the disease: blood pressure according to the classical definition of 
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severe pre-eclampsia, thrombocytopenia, impaired liver function, progressive renal 
insufficiency, pulmonary oedema, new-onset cerebral or visual disturbances. The classic 
definition could also be updated by taking into account the current knowledge of the 
pathology of pre-eclampsia. Using vasoactive markers, PlGF and s-Flt1, pre-eclampsia can be 
divided into angiogenic and non-angiogenic subgroups (33). Early-onset and severe pre-
eclampsia seem to predominantly form the angiogenic subtype while the non-angiogenic 
subtype has milder and later course of the disease (34). Pre-eclampsia can also develop in the 
postpartum period, including pre-eclampsia with severe systemic organ involvement and 
seizures (32,35). One-third of all eclamptic seizures occur in the post-partum period (35).
These cases are called late postpartum pre-eclampsia and late postpartum eclampsia and the 
pathophysiology of these phenomena is unknown. The definitions based on pathophysiology 
are discussed more closely later in the paragraph on pathophysiology. 
Public health burden
Pre-eclampsia affects 2-8% of all pregnancies (1). In Finland, according to the combined data 
from the National Medical Birth Registry and Care Register of Health Care, at the National 
Institute for Health and Welfare of Finland in year 2013, 2.5% of babies were born from pre-
eclamptic pregnancies, of which 24% were severe, and 8% early-onset subtypes of pre-
eclampsia. Similar rates have been reported in other Nordic countries. In the Danish hospital 
discharge register 2.7% of the women who gave birth in Northern Sealand from 1998-2000
had pre-eclampsia (2) and in the Norwegian Medical Birth Registry data of 1.7 million births
from years 1967 to 1992, the pre-eclampsia rate was 2.2% (3). While no validation studies 
have been performed for pre-eclampsia in the Finnish healthcare registers, studies of the 
Norwegian (36) and Danish (2) registries have been validated using medical records and in 
both studies the prevalence of pre-eclampsia in the study populations were relatively similar 
whether obtained from registry or whether based on medical records. 
Pre-eclampsia and its consequences are important causes of both maternal and newborn 
morbidity and mortality. Every year an estimated 62,000 to 77,000 women worldwide die due 
to pre-eclampsia and its complications. That is almost 18% of all maternal deaths (28,29)
most of these in developing countries. For comparison, during years 1972-2005, there were
117 direct maternal deaths (caused by a disease or its management during gestation) in 
Finland. The maternal mortality ratio was 5.6 per 100,000 (deaths per 100,000 live births)
(37). During that time, there were 15 maternal deaths per about 2 million live births due to 
pre-eclampsia or its complications, 12.4% of all maternal deaths. The significance of 
organised maternity care is emphasised by the fact that between years 1926-1937 there were
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93 maternal deaths per 100,000 births in the Women’s hospital in Helsinki and 264 in Vyborg
hospital (38). Althought maternal death is rare in developed countries, the burden of pre-
eclampsia and its consequences on health care systems is enormous. Women with pre-
eclampsia have a 3- to 25-fold increased risk of severe pregnancy complications (39). In 
developing countries, pre-eclampsia and its complications cause 25% of all stillbirths and
neonatal deaths (40). In a Norwegian study of 21,000 pre-eclamptic pregnancies, the risk of 
fetal death was remarkably high for early-onset pre-eclampsia (41). At 26 weeks of gestation,
the relative risk of fetal death was 86-fold higher, compared to pregnancies without pre-
eclampsia. This risk declined as gestation advanced, however, though still more than 7-fold 
higher at 34 weeks of gestation.
Complications
Maternal complications of pre-eclampsia include eclampsia, stroke, placental abruption, 
HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), disseminated 
intravascular coagulation, liver haemorrhage or rupture, pulmonary oedema, adult respiratory 
syndrome, acute renal failure, and death (1,42) (Table 2).
Table 2. Maternal and fetal complications of pre-eclampsia
Central nervous system Eclampsia (seizures), cerebral haemorrhage (stroke), cerebral 
oedema, cortical blindness, retinal blindness
Renal system Renal cortical necrosis, renal tubular necrosis
Respiratory system Pulmonary oedema, laryngeal oedema
Liver Jaundice, HELLP syndrome*, hepatic rupture
Coagulation system Disseminated intravascular coagulation
Placenta Placental dysfunction, placental infarction, placental abruption
Fetus Death, intrauterine growth restriction, preterm birth and their 
complications
* Haemolysis, elevated liver enzymes, and lowered platelets
In general, pre-eclampsia increases the rates of cardiovascular, respiratory, central nervous system, 
renal, hepatic and other maternal morbidity, and women with early-onset pre-eclampsia have 
significantly higher rates of maternal morbidity than women with late-onset pre-eclampsia (43).
Pre-eclampsia reduces the woman’s health-related quality of life and increases the risk of 
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postpartum depression (44-46). Perinatal consequences include stillbirth, preterm delivery, FGR,
neonatal complications, and later sequelae (47). In Finland, 8% of all pre-eclamptic pregnancies 
were early-onset, meaning deliveries before 34+0 weeks and almost a quarter were preterm, before 
37+0 weeks of gestation. Preterm birth in pre-eclampsia is usually due to iatrogenic labour, induced 
labour or caesarean section, because, at present, ending the pregnancy is the only treatment for 
pre-eclampsia. Preterm birth prolongs newborn hospitalisation and the earlier the delivery the 
more pervasive the problems. Complications associated with premature birth include respiratory 
distress, hypoglycaemia, jaundice, feeding difficulties, and more severe in very premature 
newborns; kernicterus, seizures, periventricular leucomalasia (48). Preterm delivery, as well as, 
pre-eclampsia itself, elevates the risk of bronchopulmonary dysplasia (49) and cerebral palsy
(46,50).
Long term consequences of pre-eclampsia
The long-term maternal risks after pre-eclampsia are chronic hypertension, stroke, and ischemic 
heart disease (5,6). Pre-eclampsia in any previous pregnancy is an independent risk-factor for 
coronary artery disease (51). Women who have had early-onset pre-eclampsia have an almost 
eight times higher risk of dying from ischemic heart disease than women without hypertensive 
pregnancy complications (52). Women with recurrent pre-eclampsia may have underlying 
pathological diseases, which increase their risk for hypertensive and cardiovascular disease (6).
Genetic factors that increase the risk of cardiovascular disease may also be linked to pre-eclampsia
(52). It has not been studied whether prevention of pre-eclampsia affects the risk of later 
cardiovascular complications. However, it is important for women to become aware of these risks, 
since, with lifestyle interventions, it is possible to influence them. 
Children and adults born from pre-eclamptic pregnancies have increased risks of long-term 
cardiovascular and other diseases (7,8). For example, those born from hypertensive pregnancies 
between years 1934-1944 in Helsinki, had twice the risk of stroke (53) and four times the risk of 
depression than adults not born from hypertensive pregnancies (10). They had, as well, a lower 
cognitive ability and greater cognitive decline up to old age (9,54). Children born from 
pregnancies with gestational hypertension are at an increased risk of type 2 diabetes mellitus in 
adult life (55) and the association between low birth weight and cardiometabolic disease is well 
established (56-58). This association is mostly attributable to poor fetal growth, although preterm 
birth is also independently associated with adult cardiometabolic risk factors. Pre-eclampsia is 
likely to contribute in part to these associations. For example, a recent individual-participant meta-
analysis on blood pressure in adults born preterm at very low birth-weight (VLBW) showed that 
this association is strongest among VLBW offspring exposed to maternal pre-eclampsia, but it is 
also present in VLBW offspring whose mothers did not have pre-eclampsia (59). Part of the risks
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may reflect common genetic risk factors of pre-eclampsia and cardiovascular diseases, but part is
thought to reflect fetal programming during pregnancy. The long-term risk attributable to fetal 
programming could in theory be reduced through prevention or improved management of pre-
eclampsia, but this has not been studied. 
Aetiology and pathogenesis of pre-eclampsia
Aetiology
Pre-eclampsia is a multi-systemic syndrome. Despite active research and knowledge of the risk 
factors, the cause of pre-eclampsia is still largely unknown. Different causal models may be 
speculated (60). In the mono-causality model one known exposure is both necessary and sufficient 
to cause disease. An example is a single gene with high penetrance. Multiple-causality refers to a 
model described in terms of sufficient and necessary causes (60,61). In that model, a cause of a 
disease is an event, condition or characteristics that precedes the disease and is necessary for the 
disease to occur. A sufficient cause refers to a complete causal mechanism. A disease can be 
caused by more than one causal mechanism, and recognised causes of the disease are neither 
necessary nor sufficient to produce the disease. The multiple-causality model can be applied to 
pre-eclampsia. However, the threshold liability model is suggested by Trogstad and colleagues
(60) as the best fitting model on pre-eclampsia based on the current knowledge (Figure 1).
Figure 1. The liability model explaining the risk of pre-eclampsia. Genetic, pregnancy 
specific and environmental factors all add to the woman’s basic liability to pre-eclampsia.
Modified from Trogstad et al (60).
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The model assumes that genetic action is additive, and that the phenotype reflects the summed 
effect of a number of genetic and environmental factors, each with small or moderate influence. In 
that model, maternal susceptibility genes set a liability to pre-eclampsia, which are influenced by 
fetal genes and environmental factors. Thus, the risk of pre-eclampsia may differ between 
pregnancies, depending on maternal compatibility with the fetus, change of maternal weight or 
other environmental or maternal factors that may be subject to change between pregnancies. 
Pathogenesis
Regarding the pathogenetic background of pre-eclampsia, we know slightly more than the 
syndrome’s aetiology. The symptoms of pre-eclampsia reflect the maternal endothelial 
dysfunction, which is a consequence of a complicated cascade of events. The placenta is essential 
in the development of pre-eclampsia, and pre-eclampsia may develop without a fetus, for example 
in hydatiniform mole pregnancies (62). The defects in placentation, which later lead to clinical 
pre-eclampsia, already emerge in the early weeks of gestation. Between the 8th to 18th weeks of 
gestation, the cytotrophoblasts of fetal origin invade decidua and enter the lumina of the uterine 
spiral arteries. These invaded spiral arteries go through remodelling and lose their smooth muscle 
and become widely dilated, turning into large-caliber capacitance vessels capable of providing 
adequate placental perfusion (63-65). This remodelling is necessary for normal placental function. 
In pre-eclampsia, remodelling is incomplete. The cytotrophoblast invasion of the decidua is 
shallow, limited to the superficial decidua and the myometrial segments of the spiral arteries 
remain narrow and high-resistance (11-13). Poor placentation is the first stage in the two-stage 
model of the pathogenesis of pre-eclampsia. The contributors in early placental vascular 
development and trophoblast invasion may be hypoxia, perturbation of the renin-aldosterone-
angiotensin II axis, excessive oxidative stress, inflammation, immune maladaptation, and genetic 
susceptibility. This first stage takes place in the first half of pregnancy without clinical findings of 
pre-eclampsia (66) and is followed by the second stage with endothelial damage. The endothelial 
dysfunction is induced by antiangiogenic factors, systemic inflammation, immunologic factors, 
and hypoxia, which all contribute to the development of this heterogenous condition (13). It is 
unknown whether these are interrelated, have synergistic effects or act independently (13). The 
result is vasoconstriction, end-organ ischaemia and increased vascular permeability (14).
The imbalance of angiogenic factors plays a crucial role in the pathogenesis of pre-eclampsia (15)
VEGF is necessary for glomerular capillary repair and in maintaining the health of the 
endothelium (13) particularly in the kidney, liver, and brain (15) PlGF is a potent angiogenic 
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growth factor with structural homology to VEGF-A and is thought to amplify VEGF signalling
(67,68) (Figure 2).
Figure 2. Vascular dysfunction in pre-eclampsia. The endothelial monolayer requires vascular 
endothelial growth factor (VEGF), placental growth factor (PlGF), and transforming growth factor-
(TGF- ) to function normally via activation of nitric oxide (NO). In pre-eclampsia, the VEGF 
protective signal is comprised due to an excess of soluble Flt-1 (sFlt-1), which is compounded by 
decrease in the expression of PlGF and a rise in circulating soluble endoglin (sEng), which binds and 
neutralizes TGF- . eNOS=endothelial nitric oxide synthase , HO=heme oxygenase , VEGFR=vascular 
endothelial growth factor receptor. Modified from Ahmed A (68).
PlGF is expressed early in pregnancy by the placenta. In men and non-pregnant individuals, low 
levels are produced by the heart, lung, thyroid, skeletal muscle, and adipose tissue (69). VEGF and 
PlGF have a common receptor, VEGF receptor-1, also called Flt-1 in endothelial cells. Its soluble 
variant, sFlt-1, binds to both PlGF and VEGF and inhibits their binding to endothelial cell surface
receptors. In pre-eclamptic women, expression of sFlt-1 is upregulated in the placenta (15) and an 
increase in serum sFlt-1 seems to precede the clinical syndrome (16-18). Maynard and colleagues
(15) first presented that sFlt-1 given to pregnant rats induced hypertension, proteinuria and 
glomerular endotheliosis (typical histological findings in pre-eclamptic kidneys). Excessive anti-
angiogenic activity causes pre-eclampsia-like syndrome in non-pregnant experimental animals and
non-pregnant humans being treated with VEGF antagonists for cancer (70). An experimental study 
of extracorporeal apheresis of sFlt-1 in early-onset pre-eclampsia has been conducted, and it 
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lowered sFlt-1 levels, reduced proteinuria and stabilised blood pressure without any adverse 
effects (71).
Another anti-angiogenic, placenta-derived factor, soluble endoglin (sEng), is upregulated in pre-
eclampsia (68,72,73). Both sFlt-1 and sEng are released from syncytiotrophoblasts of the placenta.
sEng binds and neutralises transforming growth factor (TGF- ), a proangiogenic and an anti-
inflammatory factor (74) sEng acts synergistically with sFlt-1. In pre-eclamptic women, they 
contribute to the endothelial dysfunction and hypertension, proteinuria, glomerular endotheliosis, 
HELLP syndrome, and restriction of fetal growth (73). The molecular mechanisms that regulate 
their release are not thoroughly identified, except that cytokines and angiotensin-1 (AT1) receptor 
autoantibodies increase (75) and heme oxygenase-1 (HO-1) inhibits their release (76).
Recently, the HO-enzyme has garnered interest in pre-eclampsia research and may play an 
important role in the syndrome’s pathogenesis. HO has antioxidant and anti-inflammatory effects, 
and tissue protective actions, which lead to the inhibition of atherogenic processes in the
cardiovascular system. The HO enzyme exists in two forms, HO-1 and HO-2 (77). The products of 
HO are bilirubin and carbon monoxide (CO). Bilirubin has anti-complement and anti-oxidant 
effects. CO has anti-platelet (78) and vasodilatory properties, and it reduces perfusion pressure in 
the placenta. HO-1 is upregulated in states of hypoxia and ischaemia. HO-1 promotes angiogenesis
(79) and increased expression of the HO-1 coding gene Hmox-1 inhibit the production of sFlt-1
and sEng (68). The expression (80) and activity of Hmox-1 are suppressed in the pre-eclamptic 
placenta. 
Endothelin-1 is a 21 amino acid peptide secreted by vascular endothelial cells and placental 
syncytiotrophoblasts, and is the most potent vasoconstrictor known (81,82). It is elevated in 
pregnant women with pre-eclampsia, and some studies indicate that the level of circulating 
endothelin-1 correlates with symptom severity and plasma sFlt-1 levels (83,84). In pregnant rats,
hypertension induced by placental ischaemia, chronic infusion of sFlt-1, tumour necrosis factor-
or angiotensin II type 1 receptor can be completely attenuated by antagonism of the endothelin-1
receptor type-A found in vascular smooth muscle (83,84). Therefore, it is suggested that
endothelin-1 could be the common pathway linking factors produced by placental ichemia to 
elevations of blood pressure and may be a future target for pharmacological interventions (81,82).
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Defining pre-eclampsia on the basis of pathogenesis
Since knowledge of the pathogenesis of pre-eclampsia has increased, it may become necessary and 
practical to update the definitions of the disease. Pre-eclampsia has been classified into early-onset
and late-onset subtypes on the basis of the timing of the clinical findings. Division into placental 
and maternal pre-eclampsia has also been used. Both classifications express the same phenomenon 
of two extremities of this syndrome with differing in the onset of the pathophysiological changes 
and clinical findings, the severity of the disease, the presence or absence of placental dysfunction 
and FGR and differences in the predisposing clinical risk factors. These subgroups (early/late, or 
placental/maternal), are also different in genetic risk and inheritance (85).
Egbor and collegues compared placental morphology in pregnancies complicated by early- and 
late-onset pre-eclampsia with controls (86). Placentas of early-onset pre-eclampsia differed
significantly from those of late-onset pre-eclampsia by weight, volume of intervillous space, 
terminal villous volume and surface areas of the terminal villi (86). Placentas from late-onset pre-
eclampsia were morphologically similar to placentas from gestational-age-matched controls, 
suggesting two subtypes of pre-eclampsia and supporting the hypothesis of predominantly
maternal and placental disease.
Staff and colleagues have proposed redefining pre-eclampsia on the basis of placental contribution 
to the syndrome (33). They reasoned that current definitions of high blood pressure and proteinuria 
are clinical signs, which are tertiary, maternal features. Placental markers, like PlGF, reflecting 
placental pathology, and FGR may be more sensitive and specific diagnostically. In women with 
FGR, similar changes in the vasoactive markers as in placental pre-eclampsia are seen, reflecting 
poor placentation. It is unknown why poor placentation does not always stimulate hypertension 
and proteinuria, but only FGR. It is suggested that this reflects interaction of fetal and maternal 
predisposing factors (33).
Prediction of pre-eclampsia
A great effort on finding tools to predict pre-eclampsia before the clinical onset of the disease  has 
been committed. Demographic factors, biochemical markers, or biophysical findings may offer 
clinical tools in the prediction. An ideal biochemical marker plays a central role in a disease’s
pathogenesis, applies early or before the clinical manifestations, is easy and inexpensive to test for,
shows a high sensitivity and specificity to the disease in question, correlates with the severity of 
the disease, and is not-detected or detected in only low levels in normal pregnancies (27). The 
pathogenesis of the pre-eclamptic placenta initiates in the first trimester and the process begins to 
emerge early. From a preventive point of view, to be able to influence this process it is important 
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to identify the at risk women in early gestation. However, it is unlikely that any single biomarker 
would perform well in the prediction of this multi-systemic syndrome involving variety of risk 
factors and heterogeneous aetiological and pathophysiological factors among women who go on to 
develop pre-eclampsia.
Clinical risk factors
Clinical risk factors may be used in the prediction of pre-eclampsia. Duckitt and Harrington
conducted a systemic review of 52 controlled studies to determine the risk of pre-eclampsia 
associated with factors that may be present at antenatal booking (Table 3) (85). They reported that 
the risk factors causing the highest risk for pre-eclampsia are a history of pre-eclampsia and the 
presence of antiphospholipid antibodies.
Table 3. Risk factors for pre-eclampsia
Risk factors Increased risk 
Nulliparity 3 fold a,b
Pre-eclampsia 7-8 fold a,b
Multifetal pregnancy 3 fold b
Prior placental abruption 2 fold b
Prior stillbirth 2 fold b
Chronic hypertension 5-10 fold a,b
Obesity 3 folda,b
Diabetes – insulin dependent 4 folda,b
Maternal age over 40 1.5 -2 folda,b
Antiphospholipid antibodies* 3-10 fold a,b
Systemic lupus erythematosus 3 b
Renal disease 2-3 fold a,b
Family history of pre-eclampsia 3 fold a
Use of assisted reproductive technology 2 fold b
* anticardiolipin or lupus anticoagulant antibodies
a Duckitt and Harrington 2005
b Bartsch et al 2016
Pre-eclampsia in the first pregnancy increased the risk of pre-eclampsia seven-fold in the 
second pregnancy (85). Recurrent pre-eclampsia and the presence of antiphospholipid 
antibodies (anticardiolipin or lupus anticoagulant or both) increased the risk of pre-eclampsia 
almost ten-fold. Pre-existing diabetes and a pre-pregnancy body mass index (BMI) of 35 
kg/m2 or over almost quadrupled the risk. Nulliparity, a family history of pre-eclampsia, and a
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twin pregnancy almost tripled the risk. Neither the chorionicity nor the zygosity alters the risk 
in a twin pregnancy, however (87,88). Maternal age 40 years or over, BMI 30 kg/m2 or over at 
booking, and a systolic blood pressure of 130mmHg or higher at booking doubled the risk. 
The meta-analysis by Bartsch and collegues showed parallel findings (89). Duckitt and 
Harrington also reported an increased risk of pre-eclampsia with pre-existing renal disease, 
chronic autoimmune disease, and a period of ten years or more between pregnancies, but they 
were not able to specify the magnitude of the increase. 
Uterine artery Doppler ultrasound measurements
Uterine artery blood flow can be measured by Doppler ultrasound examination. In the non-
pregnant uterus and in very early pregnancy, the uterine arteries have high flow resistance,
with high systolic and low diastolic blood flow. A physiological early diastolic notch may be 
present. Resistance to blood flow gradually drops during gestation as a greater trophoblastic 
invasion takes place. An abnormally high resistance can persist in women who go on to 
develop pre-eclampsia and intrauterine growth restriction (IUGR). The early defects of 
placentation and the resulting abnormalities in uteroplacental blood flow characteristic of pre-
eclampsia are reflected in the uterine arteries by an increased resistance to blood flow (90).
This results in an abnormal waveform pattern that can be evaluated by Doppler ultrasound 
measurements (91,92) analysing the resistance or pulsatility indices (RIs or PIs) or persistence 
of a unilateral or bilateral diastolic notch (Figure 3).
The utility of these measurements in the prediction of pre-eclampsia and small for gestational 
age (SGA) have been studied extensively. In a systematic review and meta-analysis by 
Cnossen and colleagues (93) the use of uterine artery Doppler ultrasonography in pre-
eclampsia prediction was evaluated from 74 studies on pre-eclampsia (total of 79,547 women) 
and 61 studies of SGA (total of 41,131 women). That meta-analysis revealed that abnormal 
uterine artery waveforms are a better predictor of pre-eclampsia than of SGA. The PI, alone 
or combined with notching, is the most predictive Doppler index. According to that meta-
analysis, and other research, uterine artery Doppler ultrasonography provides a more accurate 
prediction when performed in the second trimester (after the 16th week of gestation) than in
the first trimester. An elevated PI with notching was the best predictor of pre-eclampsia in the 
second trimester in both high- and low-risk women (positive likehood ratio of 21.0 among 
high-risk patients, and 7.5 among low-risk patients in the second trimester, and negative 
















































































































































The best predictor of severe pre-eclampsia in low-risk women was PI (positive and negative 
likehood ratio 15.6 and 0.23, respectively) and bilateral notching (positive and negative likehood 
ratio 13.4 and 0.37, respectively). Doppler assessment showed no diagnostic characteristics in the 
prediction of severe pre-eclampsia in high-risk women or pre-eclampsia in the first trimester 
altogether. Doppler ultrasound measurement of uterine arteries, however, has a significant role in 
the risk-analysis algorithms, which combine different indices in the first trimester to predict the 
risk for pre-eclampsia.
Biochemical markers
Placental angiogenic and anti-angiogenic factors
In normal pregnancy, in the early first trimester, vasoactive markers produced by the placenta are 
elevated, with sFlt-1 concentrations over ten-fold and PlGF over two-fold higher than in the non-
pregnant state. In men and non-pregnant women, low levels of PlGF are produced by heart, lung, 
thyroid, skeletal muscle, and adipose tissue (69). In pregnancies ending in early miscarriage, both 
sFlt-1 and PlGF concentrations, measured at gestational weeks six to ten, are significantly lower 
than in pregnancies that result in live birth (94). The concentration of PlGF continues to increase 
in the maternal blood until the end of the second trimester and decreases during the last two 
months of normotensive pregnancies, whereas sFlt-1 stays constant until the last two months,
when it starts to increase (16,70,95) (Figure 4). In normal pregnancy, PlGF concentrations
decrease with maternal weight, and in cigarette smokers (96).
Maynard and colleagues (15) first reported that elevated concentrations of sFlt-1 circulates in the 
plasma of pre-eclamptic women, which leads to reduced PlGF and VEGF concentrations and in 
endothelial dysfunction. Levine and colleagues (16) first showed that changes in PlGF and sFlt-1
concentrations occur earlier and are more pronounced in women who will develop pre-eclampsia 
compared to normotensive pregnancies. In pregnancies with early-onset pre-eclampsia and pre-
eclamptic pregnancies associated with an IUGR, these changes are further exaggerated (16,96).
Therefore, these biomarkers have been of high research interest. Neither of these, however,
performs in the first trimester as a sole marker in the prediction of pre-eclampsia. PlGF, though,
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has an important role in risk estimation algorithms, which seem to work well in the prediction of 
early-onset pre-eclampsia (Table 4). 
Figure 4. PlGF and sFlt-1 in normal pregnancy and in pregnancy with established preeclampsia. In normal 
pregnancy, PlGF concentrations rise until 29-32 weeks of gestation and fall then towards term. sFlt-1
increases towards the end of gestation. At term both markers approach the concentrations of established 
pre-eclampsia. Modified from Redman C and Staff  C (70).
In the second and third trimester, these vasoactive markers provide predictive information. They 
may be used as a tool when planning a monitoring schema for those women who are at increased 
risk of pre-eclampsia or show the first clinical signs of the disease. Stepan and colleagues 
suggested in a review that the sFlt-1/PlGF ratio could be used in the follow-up of women at high 
risk for pre-eclampsia at an asymptomatic stage and in clinical decisions with women having 
signs and symptoms of pre-eclampsia (97).
Pregnancy-associated protein A
Pregnancy-associated protein A (PAPP-A) is mainly produced by the placenta and its 
concentration increases until the end of pregnancy (27). PAPP-A reflects placental function. It is
involved in growth and repair processes. Its concentration has an interesting dual meaning (98) in 
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healthy conditions, like normal pregnancy, PAPP-A is increased and contributes to anti-
inflammatory, anabolic and reparative processes, raised concentrations indicate a healthy state. In 
active disease states, for example in acute coronary symptoms, raised levels relate to ongoing 
morbidity and poor outcomes, and may indicate a compensatory increase in expression.  
Interestingly, one of PAPP-A’s main functions is to allow free insulin-like growth factor to 
interact with its cell membrane protein, and consequently activates the synthesis of NO, with its 
multiple protective actions on the cardiovascular system. 
In pregnancy, PAPP-A measurement is used in the screening for fetal chromosomal abnormalities
at gestational weeks 11+0- 13+6 together with human chorionic gonadotropin- ) and nuchal 
translucency thickness (99). In pregnancies affected by trisomy 21, PAPP-A levels are lower than 
in pregnancies with normal fetal chromosomes (100). Lower levels of PAPP-A in the first
trimester in pregnancies with fetuses with normal chromosomes are associated with increased risk 
for pre-eclampsia, IUGR, SGA and preterm delivery (101-103). With extremely low PAPP-A
concentrations (under 0.3 multiples of median (MoM)), the risks of aneuploidy, spontaneous 
abortion, preterm delivery, and SGA newborn increase with decreasing concentrations (104). In 
the first trimester the screening performance of PAPP-A is only 10-20% as a single predictive 
marker for pre-eclampsia (105,106). However, it performs better in risk estimate algorithms with 
other predictive variables. 
Placental protein 13
Placental protein-13 (PP-13) is produced by placental trophoblast cells (107). In normal 
pregnancies, serum PP-13 levels slowly rise with gestational age (27). In women who 
subsequently develop pre-eclampsia, PP-13 levels are lower in the first trimester (108,109) and
with early-onset or severe pre-eclampsia, these findings are more pronounced (108,110).
Different studies have produced differing information on the performance of PP-13 as a 
predictive marker (111,112). Detection rates are not high enough to enable using PP-13 as a 
single biochemical marker in the prediction of pre-eclampsia. For example, when combining PP-
13 with Doppler ultrasound PI measurement, the prediction rate in early pregnancy was 71% at a 
false positive rate of 10% in a study by Khalil and colleagues (112). Another study reported a
prediction rate of 90% in the prediction of early-onset pre-eclampsia at 11+0-13+6 weeks of 
gestation in combination with Doppler ultrasound PI with a false positive rate of 10% (110).
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Free fetal haemoglobin and 1-microglobulin
Free, extracellular fetal haemoglobin (HbF) may be involved in the pathogenesis of pre-
eclampsia, and the heme- and radical scavenger 1-microglobulin (A1M) in the physiological 
defence against HbF (27,113). Increased Hb production has been demonstrated in pre-eclamptic 
placentas (114,115). It is hypothesised that Hb genes may be overexpressed in a subpopulation of 
cells in the pre-eclamptic placenta, and Hb may be released into the placenta blood vessel lumen
(114). Free Hb, and its metabolites heme and iron are potent toxins and cause endothelial damage 
and inflammation (116,117). Placental cells produce haematopoesis stimulating agents in 
response to reduced perfusion and possibly local hypoxia (114). Several Hb and hemi 
detoxification systems have been described (117). Free heme and radical neutralising A1M is
produced by liver and placenta (118). Its expression is up-regulated following exposure to Hb,
heme, and reactive oxygen species (115). In women who subsequently develop pre-eclampsia,
both HbF and A1M are significantly elevated in the first trimester (115). There are promising 
results of studies evaluating HbF and A1M in the prediction of pre-eclampsia in the first trimester
(115,119). Combining these two biomarkers with maternal clinical risk factors may serve as a 
prediction model for pre-eclampsia (120).
Genetic risk factors
Pre-eclampsia tends to run in families. The estimated heritability is 54 %, according to a Swedish 
twin register study (121). Both maternal and paternal factors have been shown to contribute to the 
risk (122). A woman born from a pre-eclamptic pregnancy has over twice the risk of pre-
eclampsia compared to a woman without such a history. A man born from a pre-eclamptic 
pregnancy has a 1.5-times increased risk of fathering a pre-eclamptic pregnancy than a man 
without such a history, and moreover, if a woman’s sibling is born from a pre-eclamptic 
pregnancy, her risk of pre-eclampsia is doubled (122) (Figure 5). There are also clear differences 
in the prevalence of pre-eclampsia between ethnical groups (123) for example between white 
American and African-American women. 
Since fetus expresses both maternal and paternal genes, mechanisms have evolved to protect the
fetus from immune rejections by the mother. It is speculated that an inappropriate maternal 
immune response might influence trophoblast invasion and lead to pre-eclampsia (124).
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Trophoblasts express an unusual repertoire of human leukocyte antigens (HLA). Interactions of 
maternal, paternal and fetal genotypes of HLA may play an important role in the pathogenesis of 
pre-eclampsia (124,125).
Figure 5. Risk of parenting a pregnancy with pre-eclampsia. Modified from Skjaerven R et al (122).
The majority of candidate gene studies have been underpowered and results inconsistent. Family  
linkage studies, however, have identified susceptibility loci. For example, in Finnish pre-
eclampsia families susceptibility loci have been found in chromosomes 2 and 9 (126,127).
However, individual genes have not been pinned down. New genome-wide strategies provide 
opportunities to identify common and rare sequence variants associated with pre-eclampsia
(128,129). The InterPregGen consortium (130) has reported the discovery of the first genome-
wide significant susceptibility locus in the offsprings of pre-eclamptic pregnancies. The locus is 
near the fms-related tyrosine kinase gene (FLT1) encoding Flt-1, which has been implicated in 
pre-eclampsia. Morever, Lokki and colleagues (131) recently reported findings of maternal FLT1
sequence variants associated with lower pre-eclampsia susceptibility. Women carrying these 
variants may also have a lower incidence of heart failure later in life. 
At present, there are no genetic tests available for the prediction of pre-eclampsia. However, 
family history of pre-eclampsia has been included in the risk prediction models. Recent promising




Since pre-eclampsia is a multi-system syndrome with a great diversity of aetiological factors, it is 
unlikely, that a single biomarker could be found to predict the disease. Consequently, different 
prediction algorithms have been generated. In these, maternal history, mean arterial pressure
(MAP), PI of uterine arteries measured with Doppler ultrasound, and biochemical markers in 
different combinations are utilised (Table 4). With all combinations of predictive variables,
prediction of early-onset pre-eclampsia performs better than prediction of late-onset pre-
eclampsia. In Onwudine’s work (132) uterine artery PI together with maternal history and MAP 
find all women who will develop early-onset pre-eclampsia when 10% false positives is accepted,
and 96 % with only uterine artery PI measurements. From studies by others (93,96) however, sole 
uterine artery PI does not perform as well. An efficient combination of variables for early 
prediction of early-onset pre-eclampsia is maternal factors, (maternal history and characteristics)
included with PlGF concentrations, uterine artery PI, and MAP. PAPP-A (96,133,134) does not 
improve the performance of this combination. The best performance in the prediction study of
late-onset pre-eclampsia by Poon and colleagues (135) is a combination of maternal factors, 
uterine artery PI, MAP and a selection of biochemical markers which partially differ from the 
ones used in the prediction of early-onset disease: PlGF, activin-A, and P-selexin (135). MAP
(132) or cardiac output (136,137) which are already elevated early in the pregnancy in women 
who will later develop pre-eclamsia, do not serve as solitary variables in the prediction of pre-
eclampsia.
In a recent prospective study (138) a screening based on clinical risk factors suggested in The 
National Institute for Health and Care Excellence (NICE) and ACOG recommendations (4,32)
was compared to a risk algorithm developed by the Fetal Medicine Foundation (FMF), with a
multivariate logistic model combining maternal factors, biophysical (MAP, uterine artery PI) and 
biochemical (PlGF) measurements by O’Gorman and colleagues (134). The FMF method 
detected 100% of the very early-onset (under 32+0 weeks of gestation) and 75% of preterm (under 
37+0) pre-eclampsia, with a false positive rate (FPR) of 10.0%. The NICE guidelines detected 
41% and 35% respectively, with a FPR of 10.2% and ACOG guidelines 94% and 90% , 
respectively, with a FPR of 64.2%.
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Possible predictive factors of superimposed pre-eclampsia in women with 
chronic hypertension
Superimposed pre-eclampsia is diagnosed in a pregnant woman with CHT when new-onset 
proteinuria over 0.3 g per day is detected after 20+0 weeks of gestation. Approximately 26% of 
women with CHT develop superimposed pre-eclampsia (26). It is associated with adverse 
outcomes for both the mother and fetus (139). Women with CHT who develop superimposed pre-
eclampsia have significantly higher rates of perinatal morbidity, they significantly more often 
deliver SGA infants and before 32 weeks of gestation compared to women with CHT without pre-
eclampsia (140). Endothelial dysfunction and abnormalities in cardiac and renal function are 
proposed to contribute to the development of superimposed pre-eclampsia. 
In hypertensive men and non-pregnant women, the relationship between microalbuminuria and 
reduced NO bioavailability in association with impaired endothelial flow-mediated dilatation is 
well described. NO plays an important role in maintaining vascular homeostasis. It inhibits 
smooth muscle contraction and growth, platelet aggregation and leukocyte adhesion to the 
endothelium (141). It is a highly reactive nitrogen radical, a gas with a short half-life. Blood 
vessels produce NO by endothelial nitric oxide synthase (eNOS) from L-arginine. eNOS is 
activated by blood flow induced shear stress across the vascular endothelial cell layer and it leads 
to continuous NO release (142). ADMA is an endogenous NOS inhibitor, it competes with L-
arginine in the NO synthesis pathway. In normal pregnancy, ADMA concentrations fall until 24th
weeks of gestation, consistent with gestational changes in blood pressure, and rise to pre-
pregnancy levels at term (143). Some studies report that the albumin:creatine ratio (ACR) and 
ADMA are elevated prior to onset of pre-eclampsia compared to normal pregnancies (144,145).






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The glycocalyx is a negatively-charged mesh of membranous glycoproteins, proteoglycans, 
glycoaminoglycans and associated plasma proteins on the endothelial cell surface (148). Its 
principal glycosaminoglycans (heparin sulphate and hyaluronic acid) and core proteins 
(syndecans and glypicans) are degraded in vascular diseases, leading to breakdown of the 
vascular permeability barrier, enhanced access of leukocytes to the arterial intima that 
propagate inflammation, and alteration of endothelial mechanotransduction mechanisms that 
protect against disease (149). Vascular endothelial glycocalyx is a crucial regulator of 
vascular function, and its damage has been implicated in reperfusion oxidative injury, 
inflammation, atherosclerosis and diabetes (149-151). Disruption of the glycocalyx in the 
non-pregnant state is also associated with proteinuric disease (152) salt overload (148) and 
high concentrations of atrial natriuretic peptide (153). These all are features of CHT and 
potentially relevant to the development of superimposed pre-eclampsia. Syndecan-1 (a 
transmembrane heparin sulphate peptidoglycan) is a major constituent of the endothelial
glycocalyx . Syndecan-1 and sialic acid are shed in response to sheddases (e.g. heparanase, 
matrix metalloproteinase) and neuraminidase enzymatic activity respectively (149).
Cardiac dysfunction, defined by left ventricular systolic and diastolic dysfunction, and left 
ventricular mass index and wall thickness, has been described in women prior to the onset of 
pre-eclampsia (154) however, the contribution of pre-existing cardiac disease in women with 
CHT to superimposed pre-eclampsia is poorly understood. CHT is also associated with 
abnormalities in renal function and undiagnosed chronic kidney disease (155), but the 
involvement of subclinical glomerular and renal tubular injury to superimposed pre-eclampsia 
development is unknown. 
Free fatty acids and metabolic adaptations in pregnancy
In the non-pregnant state, higher concentrations of free fatty acids (FFA) are associated with 
lipid accumulation in multiple tissues, including liver, skeletal muscle, heart, and pancreatic 
-cells (156). This intracellular lipid accumulation in non-adipose tissues is associated with 
-cell dysfunction (157). In pregnancy,
the plasma FFA composition and concentration are dynamic and depend on many factors, 
including the state of the pregnancy, obesity, insulin resistance, and other metabolic and 
dietary conditions (158). In the first and second trimesters of pregnancy, the mother’s 
metabolism is in an anabolic state. Through enhanced lipogenesis and hyperphagia, fat 
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deposit accumulation increases (159). As the pregnancy enters the third trimester, metabolism 
switches into a catabolic state, responding to rapid fetal growth. Physiological hyperlipidemia 
involves a rise in blood triglycerides and cholesterol (160,161). Maternal triglycerides do not 
cross the placenta, but, by the hydrolysing action of lipases, they are released to the fetus as
FFAs (159). Lipolytic activity of the adipose tissue becomes enhanced late in the second 
trimester, increasing plasma levels of FFA and glycerol (162). There is a positive linear 
relationship between plasma FFAs and maternal age, nulliparity and prepregnant BMI (163).
It is thought that maternal hypertriglyceridemia benefits the fetus and newborn in several 
ways (159). Under fasting conditions, triglycerides can rapidly be used for energy by ketone 
body synthesis in the liver, and they also provide a source of essential fatty acids to the fetus
from the maternal diet. Essential fatty acids (EFA) and long-chain polyunsaturated fatty acids 
(LCPUFA) are important in cell growth and development (164) and in mediating intracellular 
gene expression (165). These are important in fetal development during the third trimester 
and in the neonatal period. The fetus depends on placental transport completely for the supply 
-linolenic acid EFAs. More than 90% of fetal fat deposition occurs in the last 
10 weeks of gestation (166). LCPUFAs are higher in fetal than in maternal circulation and the 
composition is different (164,167). Fetal production of LCPUFAs, arachidonic acid and
docosahexaenoic acid, is very low, but there is active uptake by the placenta (166). The fetal
brain and retina are very rich in LCPUFAs, especially arachidonic acid and docosahexaenoic 
acid (168-170) which the placental membrane fatty acid binding protein (p-FABPpm)
preferentially binds to compared with linoleic and oleic acid (171). Modification of pregnant 
mothers’ dietary fat intake does not affect the cord and neonatal lipid levels (172).
Metabolic characteristics of pre-eclampsia include reduced glucose utilisation, 
hyperinsulinemia and hyperlipidemia (20) and many other known cardiovascular risk factors 
(21-24). These metabolic changes are seen both in normal pregnancies and in pre-eclampsia, 
but are exaggerated in pre-eclampsia, and are likely to have evolved to meet the metabolic 
demands of the growing fetus (159). Circulating FFAs are key regulators of glucose 
metabolism and have been shown to increase in pre-eclamptic women long before clinical 
onset of the disease (173-177). High plasma lipids may contribute to the development of pre-
eclampsia by increasing vascular dysfunction in the uteroplacental circulation by advancing 
lipid changes in the walls of already poorly transformed spiral arteries. The atherogenic 
haemodynamic flow patterns in these pre-eclamptic spiral arteries may play a role in 
aggregating lipid deposition in the vessel wall (25). High concentrations of FFAs may 
influence several characteristics of pre-eclampsia, such as increased insulin resistance, 
disturbed endothelial cell function and altered production of vasoactive substances.
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Prevention of pre-eclampsia
Since placental changes in pre-eclampsia begin in the first trimester, women at highest risk, 
those who would benefit most from prevention of the disease, should be identified in early 
gestation. Due to the multifactorial nature of pre-eclampsia, it might be that in the future 
different subgroups of pre-eclampsia will be recommended individual preventive medication. 
Acetylsalicylic acid 
Background
Acetylsalicylic acid, or aspirin, is believed to have been used as early as 1534 BC, since the 
use of ‘salix’, aspirin-related compounds derived from willow tree bark, were documented on 
papyrus scrolls used by Egyptian physicians (178). In 1758, Reverend Edward Stone studied 
willow tree bark for the relief of headaches, myalgia and fever. The Nobel Prize in 1971 was 
awarded to Samuelson and Bergström for demonstrating the mechanism of action and clinical 
aspects of aspirin. After that, research on its antiplatelet effects was undertaken. In 1979, it 
was observed that pregnant women who took aspirin did not develop pre-eclampsia as often 
as other pregnant women (179). Results of a small randomised trial were published in the year 
1985. This trial reported that 150 mg aspirin, started at 12th weeks of gestation, prevented pre-
eclampsia, IUGR and perinatal death (180).
The preventive effect of aspirin is thought to be due to its favourable effect on prostaglandin 
production, particularly the prostacyclin:thromboxane ratio, which is in imbalance in pre-
eclamptic women before the clinical disease. Vasodilatary prostacyclin is produced in 
endothelial cells, and vasoconstrictive and aggregatory thromboxane in platelets. In normal 
pregnancy there is a predominance of prostacyclin (181). Arachinoid acid is a precursor of 
these prostaglandins. By the action of cyclo-oxygenases (COX-1 and COX-2), arachinoid 
acid is converted to prostanoids (PGH2), which are further converted to prostaglandins. Low
dose aspirin irreversibly inhibits COX-1 synthase. Since COX-1 synthase is the main cyclo-
oxygenase in platelets, the production of thromboxane is efficiently inhibited. Inhibition of 
COX-2 synthase in the blood vessel wall requires considerably higher doses of aspirin and the 
production of prostacyclin is intact with the low dosage (182). Vainio and colleagues (183)
studied this dose-dependent inhibition and the favourable effect on prostacyclin:thromboxane 
ratio was within the 0.5-2.0 mg/kg dose range.
Other possible routes of action of low dose aspirin have emerged. One of these is throught the
HO-1 pathway. Aspirin stimulates the expression and enzymatic activity of HO-1 in 
endothelial cells, presumably via NO-dependent and COX-independent pathways (184,185).
39
The increased HO-1 activity leads to the ensuing formation of bilirubin and CO, and may 
contribute to and explain the antioxidant and antiatherogenic activities of aspirin (186).
Aspirin also reduces ADMA concentration (184,185) consequently increasing endothelial NO 
synthase activity. Furthermore, aspirin dose-dependently inhibits sFlt-1 production in 
cytotrophoblasts via COX-1 inhibition (187).
Low dose aspirin has side effects as often as placebo (188) and it is safe in pregnancy due to 
the knowledge of its use on tens of thousands of pregnant women. Aspirin is contraindicated 
in patients with an allergy to aspirin or a history of peptic ulcer. One to two out of every one 
thousand users of aspirin develop intestinal haemorrhage (189). There are no long-term 
follow-up studies of the children after mothers’ consumption of low dose aspirin during 
pregnancy.  
Studies on pre-eclampsia prevention by low dose aspirin
Large meta-analyses suggest that low dose aspirin and other antiplatelet agents would benefit 
women with an increased risk of pre-eclampsia. The Paris collaboration (190) meta-analysis 
of 32,217 mothers included randomised studies regardless of the inclusion criteria. The effect 
was moderate but consistent. The relative risk (RR) of pre-eclampsia was 0.9 in women 
receiving anti-platelet agents compared to control women. The authors recommended low 
dose aspirin in high-risk women. The Cochrane review (191) updated in 2007, accepted 
studies that included women with an increased risk of pre-eclampsia and demonstrated a 17%
reduction in the incidence of the disease. Another meta-analysis (192) included 27 studies 
(11,348 women) in which the initiation of the low dose aspirin treatment could be identified. 
In those women who started low dose aspirin at 16 weeks of gestation or earlier had 
significantly reduced risk of pre-eclampsia compared to control women (RR 0.47, 95%CI 
0.34-0.65). In women who started aspirin after 16 weeks of gestation there was no effect on 
the risk (RR 0.81, 95%CI 0.63-1.03). According to meta-analyses, low dose aspirin prevents 
early-onset and severe pre-eclampsia, but does not have an effect on late-onset and non-
severe pre-eclampsia (193-196). The evidence of low dose aspirin in the prevention of pre-
eclampsia has been determined to be so strong that several organisations and expert groups
have released recommendations on its initiation in high-risk women (32,197-200) (Table 5). 
Aspirin resistance
In cardiovascular literature, the concept of aspirin resistance is well identified. Some patients 
seem to develop severe cardiovascular-related events despite the antithrombotic therapy. It is 
40
suggested that these patients are aspirin ‘resistant’, their platelets are not affected or the 
response to aspirin therapy is different compared to those who benefit from it. Some of these 
patients require a larger dose of aspirin to develop the expected antiplatelet effect. The reason 
behind this phenomenon is unclear. A too low aspirin dose, compliance issues, differences in 
abilities to absorb aspirin, or an underlying genetic disposition are suggested explanations 
(201-203). In pregnancy, enhanced platelet turnover may be an underlying cause (178).
According to a meta-analysis (204) of aspirin resistance and cardiovascular risk, the patients 
who are aspirin resistant have about a four-fold greater risk of long term cardiovascular, 
cerebrovascular, or vascular morbidity while on aspirin compared to patients with a normal 
aspirin response. In that meta-analysis, 28% of the 2980 patients were classified as aspirin 
resistant by platelet function assays. Since low dose aspirin completely inhibits COX-1
pathway, those assays that target aspirin COX pathways are appropriate in demonstrating 
aspirin resistance (178).
Statins
Statins, used to treat high blood cholesterol are currently being studied in the prevention of 
pre-eclampsia (205). They have many positive effects, but have previously been 
contraindicated during pregnancy (206). Since more experience has accumulated, it seems 
that statins can be safe during pregnancy (207). Statins have a positive effect on cytokine and 
free radical oxide production and immunomodulation, and they have anti-inflammatory 
effects. They increase the production of Flt-1 in endothelial cells by stimulating factor 1-
alpha. Statins induce HO-1 transcription and expression. HO-1 has anti-inflammatory and 
cell-protective actions, and the HO-1 pathway inhibits vasoconstrictive sFlt-1 and sEng (208).
Low molecular weight heparin
Women with placenta-mediated complications in earlier pregnancies have an increased risk of 
both recurrent placenta-mediated complications (209) and venous thromboembolism in 
subsequent pregnancies (210). Vice versa, women with previous venous thromboembolic 
complications have an increased risk of placenta-mediated pregnancy complications (211).
These are all associated with placental vascular thrombosis. Antithrombotic low molecular 
weight heparin (LMWH) has been studied in the prevention of pre-eclampsia combined with
and without low dose aspirin. The Cochrane review of LMWH in improving maternal and 
infant health outcomes did not show an effect in the prevention of pre-eclampsia (212) and in














































































































































































































































































































































































































































































































































































































































































































































































































Combined treatment of LMWH with low dose aspirin, started in the first trimester, seems to 
prevent early-onset hypertensive diseases and SGA in women with inherited thrombophilia
(214). According to a recent meta-analysis, LMWH combined with aspirin compared to sole 
low dose aspirin seems to reduce the risk of early-onset pre-eclampsia and SGA considerably 
more efficiently in women with a history of pre-eclampsia (215). Because of small number of 
women in these studies larger clinical trials are required to confirm these findings and for 
recommendations in clinical work.
Antioxidants and other dietary supplementation
Low dietary calcium and low serum calcium concentrations are associated with pre-
eclampsia. Large trials on the benefit of calcium supplementation, 1.5-2 g per day, in 
prevention of pre-eclampsia have not supported this treatment in healthy nulliparous women
(216) nor in women with a calcium deficient diet (217). However, the findings are 
controversial. In the World Health Organisation (WHO) randomised trial of over 8,000 
women with a calcium deficient diet (217) treatment significantly reduced the risk of serious 
complications from pre-eclampsia, which included maternal and neonatal morbidity and death 
and preterm delivery; the latter among young women. Daily calcium supplementation of 1.5-
2.0 grams is thereby recommended by the WHO in the second half of pregnancy in those 
women whose dietary intake is low. In Cochrane review from 2014 (218) with meta-analysis 
of 13 trials and over 15,000 women, calcium supplementi associated with a
significant risk reduction of pre-eclampsia, particularly among women with a low calcium
diet. However, the authors advise to interpret these results cautiously since they believe the 
result is overestimated due to a small-study effect or publication bias. In Finland, calcium
supplementation, 0.5-1.0 g per day, is recommended to pregnant women, depending on their
diet (219).
Oxidative stress, an imbalance between pro-oxidant and antioxidant forces, plays a part in the 
pathogenesis of pre-eclampsia. Various studies have attempted to find out if antioxidants have 
an effect on pre-eclampsia prevention. Vitamins C, E or D do not reduce the risk of pre-
eclampsia. In a 2008 Cochrane Review of antioxidants in the prevention of pre-eclampsia
(220) a meta-analysis of 9 trials and 5,500 women, vitamins C and E did not have a 
preventive effect. A meta-analysis by Rossi and Mullin (221) did not show any effect of 
vitamin C and E in preventing pre-eclampsia in subgroups of high-risk or low-risk women. In 
the International Trial of Antioxidants in the Prevention of Pre-eclampsia (INTAPP) (222)
2647 women were randomised to 1 g vitamin C and 400 IU vitamin E daily. The trial was 
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discontinued due to a concern of adverse pregnancy outcomes such as fetal loss or perinatal 
death and preterm prelabor rupture of membranes. No effect was seen in the prevention of 
pre-eclampsia, as was found in another placebo-controlled trial (223) with similar doses of 
vitamins C and E, however, in that study significantly more low birthweight babies were born 
in the antioxidant group.
Studies of vitamin D are contradictory. A recent prospective cohort (224) with 1710 pregnant 
women suggest that vitamin D concentrations at 15th weeks of gestation are not associated 
with development of pre-eclampsia. 
Physical exercise and obesity management
Regular physical exercise has various health benefits and it protects from cardiovascular 
diseases throught a with wide variety of mechanisms. By having an impact on many risk 
factors common to pre-eclampsia, physical exercise may also be important in the prevention 
of pre-eclampsia. Regular exercise reduces obesity-related markers and the risk of type 2 
diabetes by improving insulin sensitivity, endothelial dysfunction, lipid profile, oxidative 
stress and inflammatory markers (225-228). Exercise reduces visceral fat, which increases 
insulin sensitivity. A meta-analysis including 15 studies with 180,000 participants 
investigating the effect of pre-pregnancy and early-pregnancy physical activity on the risk of 
pre-eclampsia suggested a reduced risk with increasing levels of physical activity (229).
Women in the higher levels of physical activity had a 20 to 33% reduction in the risk of 
developing pre-eclampsia. The protective effect of physical exercise on the incidence of pre-
eclampsia is based on its effect on the improvement of the functional capacity of placenta and 
endothelial function (230) glycemic control and insulin resistance (231) antioxidant defences,
pregnancy-induced inflammation suppression, blood pressure reduction, and levels of total 
cholesterol, triglycerides (232,233) and leptin (234).
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AIMS OF THE STUDY
1. To investigate the concentrations of total and individual free fatty acids in pre-eclamptic 
and normotensive pregnant women and to study the relationship between free fatty acid 
concentrations and insulin sensitivity (Study I).
2. To explore predictive factors concerning the onset and severity of pre-eclampsia by using 
cluster analysis in a prospectively-collected cohort of women with known clinical risk factors 
for pre-eclampsia (Study IV).
3. To study the concentrations of sFlt-1 and PlGF and their ratio (sFlt-1/PlGF) in predicting 
pre-eclampsia in prospectively-collected serial serum samples from a cohort of pregnant 
women with clinical risk factors for pre-eclampsia, and controls with special reference to 
early- and late-onset disease (Study III).
4. To study the contribution of maternal (endothelium, cardiac, renal) and placental factors to
the development of superimposed pre-eclampsia in women with chronic hypertension (Study 
V).
5. To study the effect of low dose aspirin (100mg) started at 12+0 to 13+6 weeks of gestation 
on the prevention of pre-eclampsia and intrauterine growth restriction in high-risk women 
identified by abnormal uterine artery flow (Study II).
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MATERIALS AND METHODS
Patients and study design for the free fatty acid profiles in the pre-
eclampsia study (Study I)
The study participants, 21 nulliparous, previously healthy pre-eclamptic women and 11 
normotensive, non-proteinuric women, were recruited in the maternity clinics, the prenatal 
clinic and the antenatal ward of Helsinki University Central Hospital between January 1996 
and February 1998. Patients with severe pre-eclampsia were not included. At examination, the 
range of gestational ages was 32.3-39.3 (median 36.4) in the pre-eclamptic women and 29.0-
38.3 (median 34.4) in the control group. There were no differences in the pre-pregnancy BMI
and weight gain.
Measurements
FFAs were measured in conjunction with a 75 mg oral glucose tolerance test, with serum 
samples collected at baseline and at 60 and 120 min. No women had gestational diabetes as 
defined with concurrent Finnish criteria 
7.9 mmol/L).
As previously reported (19), the intravenous glucose tolerance test, using the minimal model 
technique, was used to measure whole-body insulin sensitivity. A dose of glucose (0.3g/kg 
glucose) was injected intravenously after overnight fast, followed by a bolus of insulin at 20 
min (0.03IU/kg insulin). Blood samples were collected at baseline with 5-min interval, and 4, 
6, 8, 10, 22, 29, 37, 67, 90, 180 min after administration of the glucose bolus. Insulin 
sensitivity was evaluated from using disappearance curves of glucose and insulin with the 
Minimal Model computer program and expressed in min-1 per 
FFA determinations
Lipids were first extracted from the serum samples using the Folch and Lees method. The 
extract was dried and reconstituted in chloroform (E.Merck, Darmstadt, Germany). Then,
lipid extract was applied to separate small amino acid columns employing a Gilson automatic 
sample pretreatment device (Middleton, Wisconsin, USA). The FFA fraction was eluted with 
2% acetic acid in diethyl ether and ether fractions were then evaporated in vacuo and FFAs
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methylated with HCl-methanol reagent. Isolated FFAs were then determined employing a gas 
chromatograph equipped with a FID detector. 
Statistical analysis
Data were analyzed by using the SPSS 14.0 software program (SPSS Inc). FFA 
concentrations were log transformed to attain normality. An independent-samples t-test was 
used to calculate differences between subjects, and adjusted for gestational age and pre-
pregnancy BMI by linear regression. A paired-sample t-test was used to calculate differences 
within subjects. All P-values are two-sided. 
PREDO - Prediction and prevention of pre-eclampsia Study Cohort 
(Studies II-V)
The multidisciplinary PREDO Project ‘Prediction and Prevention of Pre-eclampsia’ has three 
study arms: obstetric, genetic and psychological. The entire PREDO Project is described in a 
Cohort Profile publication (235). This thesis is based on the obstetric arm, for which we
recruited 947 women with risk factors for pre-eclampsia and 117 pregnant women without 
known risk factors as a comparison group at 12+0 to 13+6 weeks of gestation between 
September 2005 and December 2009. We refer to these groups as high-risk and a control
group, respectively. The psychological arm includes an additional subsample of 3698 women 
who were enrolled regardless of their risk status (236-238). The development and health of 
the children is being followed up (239-241), however that data is not part of this thesis. The 
recruitment took place when these women attended the first ultrasound screening in one of the 
ten hospital maternity clinics participating in the PREDO Project; Women’s Hospital, 
Kätilöopisto Maternity Hospital and Jorvi Hospital in Helsinki University Central Hospital, 
Kanta-Häme Central Hospital, Päijät-Häme Central Hospital, Tampere University Hospital, 
Kuopio University Hospital, Northern Karelia Central Hospital, Hyvinkää Hospital and 
Iisalmi Hospital. Table 6 illustrates the number of participants recruited from each hospital. 
We also enrolled the spouse of each study participant (biological father of the child) for the 
genetic arm. The flow-chart of Studies II-V of this thesis is shown in Figure 6.
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Figure 6. Flow chart of Studies II-V. These studies are part of the Prediction and Prevention of 
Pre-eclampsia (PREDO) Project.
Table 6.
Number of participants recruited from each hospital
Hospitals in PREDO Project Number of participants 
recruited
Helsinki University Central Hospital:
Women’s Hospitai 402




Kanta-Häme Central Hospital 28
Päijät-Häme Central Hospital 12
Tampere University Hospital 16
Kuopio University Hospital 80
Northern Karelia Central Hospital 50
Iisalmi Hospital 38
PE = pre-eclampsia, ASA = aspirin, CH = chronic hypertension
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Inclusion and exclusion criteria and definitions
The inclusion and exclusion criteria of the at-risk group of women in the PREDO cohort in 
Table 7. Women with one or more risk factors for pre-eclampsia were invited to participate 
unless any of the exclusion criteria were present. 
Samples collected
Blood and urine samples were collected at 12+0 to 13+6, 18+0 to 20+0 and 26+0 to 28+0 weeks of 
gestation and stored at -80°C.
Ultrasound measurements
We measured uterine artery blood flow by colour Doppler ultrasound transvaginally from all 
participants at 12+0 to 13+6 weeks of gestation. We identified the uterine artery at the level of 
the internal cervical os as it approaches the uterus laterally. Women who had a bilateral pre-
diastolic second-degree notch were allocated to the medication group. Women who did not 
fulfil the criteria for the medication group were allocated into follow-up groups. Those 
women who did not have any of the inclusion criteria and who did not have a bilateral second 
degree pre-diastolic notch in the uterine artery blood flow examination were recruited into the 
control group. 
Table 7. Inclusion and exclusion criteria in women recruited in the at-risk group of the 
PREDO Project
Inclusion criteria
Age under 20 or age over 40
Obesity (BMI over 30 kg/m2)
Chronic hypertension 
Sjögren’s syndrome, lupus erythematosus 
A history of one of the following conditions:
Gestational diabetes
Pre-eclampsia 
Small for gestational age (birthweight < -2 SD)
Fetus mortus (fetal death after 22 weeks of gestation or > 500 g weight in a previous pregnancy)
Exclusion criteria
Allergy to aspirin, tobacco smoking (during pregnancy), multiple pregnancy
A history of one of the following: asthma, peptic ulcer, placental ablation, inflammatory bowel 
disease (Crohn’s disease, colitis ulcerosa), rheumatoid arthritis, haemophilia or thrombophilia 
(previous venous or pulmonary thrombosis or coagulation abnormality)
BMI = body mass index, SD = standard deviation
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Outcomes
Outcome diagnoses of the PREDO cohort were: pre-eclampsia (systolic blood pressure 
dipstick equivalent in two 
consecutive measurements), severe pre-eclampsia (
, early-onset pre-eclampsia 
(diagnosis < 34+0 gestation), CHT (blood pressure 140/90 mmHg or medication for 
hypertension before 20 weeks of gestation), gestational hypertension (systolic blood pressure 
th weeks of gestation without 
proteinuria), gestational diabetes (diet treated/ insulin treated), HELLP -syndrome, eclampsia, 
SGA (< -2 standard deviation (SD), birthweight SD score as a continuous variable calculated
according to Finnish standards (242)), normal pregnancy, and fetus mortus (fetal death after 
22weeks of gestation or >500g weight) in a previous pregnancy. Each individual outcome 
diagnosis was determined by a jury, which consist of two physicians and a study nurse, who
met face-to-face and reviewed the hospital and maternity clinic records of each participant. 
Patients and methods for the cluster analysis (Study IV)
Participants and outcomes
Those 903 women who had risk factors for pre-eclampsia were included in the cluster 
analysis. Women (n=69) who were randomised to receive low-dose aspirin were excluded 
from this substudy. 
Primary outcomes for the study were pre-eclampsia two 
(4), gestational hypertension 
(new onset hypertension after 20 weeks of gestation, without proteinuria), and birth weight 
SD score as a continuous variable calculated according to Finnish standards (242).
Secondary outcomes were early-onset pre-eclampsia (delivery before 34+0 weeks of 
gestation), late-onset pre-eclampsia (delivery at or after 34+0 weeks of gestation), preterm pre-
eclampsia (delivery before 37+0 weeks of gestation), term pre-eclampsia (delivery at or after 
37+0 weeks of gestation), intermediate pre-eclampsia (delivery between 34+0-36+6 weeks of 
gestation), severe pre-
-2SD), gestational diabetes 
(diet or insulin treated), CHT (
weeks of gestation), HELLP syndrome and fetal demise (fetal death after 22nd gestational 
week or over 500g weight).
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Methods 
We applied a Bayesian clustering algorithm based on mixtures of binary variables, see, e.g. 
(243) using an implementation available in the Bayesian Analysis of Population Structure 
(BAPS) software (244) to classify the study participants on the basis of their risk factors. The 
algorithm detected 25 clusters, corresponding to different risk factor combinations.  For each 
cluster detected, we computed the risk ratio of each disease outcome, relative to the risk in the 
general population. The significance and CIs of the risks in the different clusters were 
computed using the exact binomial test (function binom.test in the R software). The false 
discovery rates (FDR) were computed using the function p.adjust in R. 
The risk for pre-eclampsia and its subtypes in the general Finnish population for these 
outcomes were estimated according to data from the National Institute for Health and Welfare 
registers (Medical Birth Register and Care Register for Health Care) from the year 2013; pre-
eclampsia 2.5% (of those 24% severe, 8% early-onset, 15% intermediate, 77% term, 23% 
preterm) with frequences obtained by request from the register authorities, and gestational 
hypertension 4.4%, SGA 2.3%, and gestational diabetes 9%. 
Vasoactive agents for the prediction of early- and late-onset pre-eclampsia  
(Study III)
Subcohort
In this substudy we included 26 women with risk factors for pre-eclampsia who eventually 
developed the disease. The first control group was formed from 26 women with risk factors 
for pre-eclampsia who did not develop the disease. They were chosen by computerised 
randomization. The second control group was formed with 53 women without clinical risk 
factors and without pre-eclamptic pregnancy. One woman without risk factors was included 
in the pre-eclampsia group, since she developed the disease. 
Sample collection and assays
Serum samples from all three trimesters were included in the analysis. Serum sFlt-1 and PlGF 




Data were analysed with the SPSS 19.0 program. For comparisons between groups Student t-
tests and analysis of variances (ANOVA) were used as appropriate. For multiple comparisons 
Bonferroni adjustment was used. The nonparametric Kruskal-Wallis test was used since the 
sizes of the groups differed and for correction: post hoc test pairwise comparisons with 
adjusted significance and to compare concentrations (PlGF and sFlt-1) and the sFlt-1/PlGF 
ratio between the four groups. 
The change in the concentration (PlGF and sFlt-1) or ratio (sFlt-1/PlGF) between 
measurements was calculated for each individual and for comparison of sequential changes 
between the first and second, and the second and third measurement. For comparison of these 
changes between the four study groups the non-parametrical Kruskal-Wallis test was used. To 
determine the predictive value of PlGF and the sFlt-1/PlGF ratio at the second and third 
measurement point, receiver -operating characteristic (ROC) analysis was performed. 
Patients and methods for the analysis of predisposing factors of 
superimposed pre-eclampsia in chronic hypertension (Study V)
All women of the PREDO project with CHT were included in this substudy and those healthy 
controls with the greatest sample availability. Samples from the entire cohort (522 samples 
from 90 women with CHT and 90 healthy controls at 3 timepoints) were analysed for plasma 
markers of placental function (PlGF), maternal cardiac function (B-type natriuretic peptide; 
BNP) and renal tubular injury (neutrophil gelatinase-associated lipocalin; NGAL). 
Nested case-control study
Additional markers were measured in a nested case-control study using samples which were 
available at all visits from 12 women who developed superimposed pre-eclampsia, 24 women 
with CHT who did not develop superimposed pre-eclampsia matched for BMI and age and 24 
randomly selected healthy controls. There were no demographic differences between control 
women who were included or excluded from the case-control study. 
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Validation cohort
Concentrations of plasma biomarkers that were significantly different between women with 
and without superimposed pre-eclampsia were validated in a second cohort of women with 
CHT and/or chronic kidney disease (CKD) with and without superimposed pre-eclampsia (at 
time of diagnosis), women with pre-eclampsia without pre-existing disease and healthy 
controls (245).
Biochemical analysis
Analysed biomarkers and methods used in Table 8.
Table 8. Measured biomarkers and methods used
Functional 
entity




Plasma-free sialic acid Chromatographic stable isotope 











Plasma B-type natriuretic 
peptide (BNP)





















Placental growth factor (PlGF) Triage PlGF Test
ELISA = the enzyme-linked immunosorbent assay, MSMS = tandem mass spectronomic method, LC = 
liquid chromatography
Statistical analysis
Demographic data are presented as medians (interquartile range, IQR) or frequencies 
(percentages). A Q-Q plot was used to explore distribution normality, and logarithmic 
transformations were used where appropriate. T-tests or the Mann-Whitney test were used to 
compare parametric and non-parametric differences between groups, respectively, and 
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Fisher’s exact test for contingency tables. To avoid multiple testing of the same hypothesis, 
data were corrected for inclusion of women who had provided multiple samples, using 
interval regression analysis with random-effect modeling for individual clustering. 
Relationships between biomarkers, maternal age, and BMI was examined with Spearman’s 
correlation.
ROC areas were used for comparison of potential predictive performance of biomarkers for 
development of superimposed pre-eclampsia. 
Sample size calculation
A sample size of 12 cases and 24 controls was calculated as adequate to detect a one SD 
difference in means of the concentration of any biomarker between cases and controls to give 
81% power at the 5% significance level.
Aspirin in the prevention of pre-eclampsia – aspirin trial and meta-
analysis (Study II)
Randomisation and blinding
This was a randomised placebo-controlled double-blinded trial. Randomisation was 
performed by the Tampere University Hospital Pharmacy. Aspirin and placebo tablets were 
prepared by a pharmaceutical company, as a paid service (Orion, Espoo Finland). Women 
with one or more risk factors (inclusion criteria Table 7) and bilateral second degree uterine 
artery notch were randomized to 100 mg per day aspirin or placebo from 12th to 35th weeks of 
gestation. 
Primary and secondary outcomes of the aspirin trial are presented in Table 9.
Table 9. Outcomes in the aspirin trial 
Primary outcomes
Pre-eclampsia (blood pressure 3 g/24 
hours or dipstick equivalent in two consecutive measurements)
Gestational hypertension
Secondary outcomes
Early-onset pre-eclampsia (diagnosed before 34+0 weeks of gestation)
Preterm pre-eclampsia (diagnosed before 37+0 weeks of gestation)
Severe pre-eclampsia (blood pressure 
5.0 g/24 hours
Small for gestational age fetus (birthweight  <-2 SD)
Severe diagnosis (early-onset pre-eclampsia and/or severe pre-eclampsia and/or SGA fetus)
SD = standard deviation
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Meta-analysis
All prospective, randomised, controlled trials, that met the following criteria were included in 
the meta-analysis: 1) included women that had abnormal uterine artery Doppler flow 
velocimetry measurements and 2) aspirin started at or before the 16th week of gestation with 
doses between 50 and 150 mg/day. The control group had to be allocated to either on placebo 
or no treatment. Through the literature search, we identified 1414 eligible studies. Only two 
studies (246,247) fulfilled the abovementioned inclusion criteria in addition to our study. The 
results were available for a total of 346 women.
The outcome measures for the meta-analysis were pre-eclampsia, severe pre-eclampsia, 
preterm and term pre-eclampsia. 
Statistical methods
Continuous variables were tested for normality. Highest proteinuria values were log 
transformed to attain normality. Independent sample t-tests were used for continuous 
s for categorical variables. Two-tailed P-values less 
than 0.05 were considered statistically significant. To compare the risk of each outcome 
between the aspirin and placebo groups RRs were calculated. 
We expected an incidence of 25% for pre-eclampsia among the study participants based on a 
previous study (246). We calculated that with a power of 0.80 and an alpha of 0.05 we would 
be able to confirm or exclude a reduction in incidence to 10% in groups of 80 participants 
each. For groups of 60 and 61 participants, which was the number included in the analysis, 
the corresponding power is 0.62. 
Studies included in the meta-analysis were combined and analysed using Comprehensive 
Meta-analysis V 2.0 software (Biostat Inc., Englewood, NJ, USA). Individual RRs were 
calculated for each study, and pooled for global analysis with 95% confidence intervals (CI). 
In case of heterogeneity global RR were calculated according to Der Simmonian and Laird 
random effect models. Heterogeneity between studies was analysed with Higgins’ I2 and 
considered to be high if over 50%. Since heterogeneity for both term and preterm pre-
eclampsia was 75%, a random effects models was used for all outcomes. For pre-eclampsia,
heterogeneity was 14%, and for severe pre-eclampsia, it was 0%. Because of the small 
number of studies, a funnel plot analysis to assess publication bias was not conducted. 
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RESULTS
Free fatty acid profiles in pre-eclampsia (Study I)
Total FFA concentrations
Total FFA concentrations at baseline were 67% higher in pre- n
normotensive pregnancies (P = 0.0002) (Table 10). This difference was no 
longer significant after an oral glucose load, which at 2 h had reduced FFA concentrations by 
40% in pre-eclamptic women, but only 24% in control women (P for interaction = 0.084). 
Table 10. Free fatty acids in women with pre-eclampsia and normotensive pregnant women at 





























































































































BMI = body mass index
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Individual FFA concentrations
Table 10 shows the concentrations of total and individual FFAs at baseline and at 2 h. At
baseline, the concentrations of individual FFAs were all higher in women with pre-eclampsia, 
with the exception of myristic acid. The differences between pre-eclamptic and normotensive 
pregnancies were largest in the concentrations of the oleic (75%), linoleic (129%) and 
arachidonic (315%) acids. After the oral glucose tolerance test, the concentrations of linoleic 
and arachidonic acids remained significantly higher in women with pre-eclampsia, whereas 
myristic acid concentrations were lower. After adjusting for BMI before pregnancy and 
gestational age the differences of FFA concentrations between pre-eclamptic and control 
subjects remained similar.
There was a group of FFAs, which were not identified. The concentration of undetermined 
FFAs was 5.9% in the pre-eclamptic group and 3.4% in the control group. 
FFA concentrations and insulin sensitivity
Insulin sensitivity in pre-eclamptic women was 37% lower (P=0.009) than in control women 
as previously reported (20).
Cluster analysis in the prediction of pre-eclampsia (Study IV)
Of the 903 women with risk factors for pre-eclampsia, 86 (9.5%) developed the disease. Of 
those with pre-eclampsia, 10 (11.6%) had early-onset disease and 36 (41.9%) severe disease. 
465 women (51.5%) did not meet any of the primary or secondary outcome criteria, whereas 
438 (48.5%) had one or more of these pregnancy complications. 
In the control group of 110 women without risk factors, 2 developed pre-eclampsia (1 of them 
severe and the other non-severe late-onset pre-eclampsia). Of women in the healthy control 
group, 87% did not meet any of our primary or secondary outcome criteria. 
Women with pre-eclampsia in a previous pregnancy, CHT, a SGA newborn, or type 1 
diabetes mellitus were at high risk of early-onset, severe, preterm and intermediate pre-
eclampsia. Pre-eclampsia in a previous pregnancy and obesity (BMI over 30 kg/m2) were the 
most important single risk factors for term pre-eclampsia. Obese women had an increased risk 
of any (Odds ratio (OR) 2.1, 95% CI 1.1-3.6), term (OR 2.3, 95% CI 1.1-4.2) and severe (OR 
5.2, 95% CI 2.1-10.5) pre-eclampsia. No association with preterm or early-onset pre-
eclampsia was observed. Obesity combined with other risk factors, CHT, and type 1 diabetes 
mellitus further increased the risk of pre-eclampsia. Type 1 diabetes mellitus without other 
risk factors increased the risk of preterm, but not term pre-eclampsia. Age over 40 or under 20 
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in a healthy woman without other risk factors did not increase the risk of pre-eclampsia in our 
cohort. Systemic lupus erythematosus was an inclusion criterion for 4 women and Sjögren’s 
syndrome for 13 women. None developed pre-eclampsia. Women with pre-eclampsia 
significantly more often had labour induced or caesarean sections, and their newborns had 
lower Apgar scores.
The risk of pre-eclampsia increased exponentially (linearly on the logarithmic scale) as the 
number of risk factors increased.
Vasoactive agents in the prediction of pre-eclampsia (Study III)
We studied PlGF and sFlt-1 (also known as VEGF-1) and the sFlt-1/PlGF ratio in 3 
timepoints (12-14, 18-20 and 26-28 weeks of gestation) in 53 women with high pre-eclampsia 
risk and 53 healthy controls. From these women, 27 developed pre-eclampsia, 6 early-onset 
and 21 late-onset forms of the disease.
PlGF
There were no significant differences in PlGF concentrations between early-onset, late-onset 
and control groups in the first trimester. By 18th to 20th weeks of gestation, significant 
differences in PlGF concentrations occurred between those who developed early-onset pre-
eclampsia and those who developed late-onset pre-eclampsia and controls without risk factors 
for pre-eclampsia (Table 11).








































Concentrations (geometric mean, 95% confidence interval) of PlGF in all four study groups. 
*P < 0.05 compared to late-onset pre-eclampsia, controls with risk factors and without risk factors
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sFlt-1
There were no significant differences in sFlt-1 concentrations between early-onset, late-onset 
and control groups in the first and second trimester. sFlt-1 was higher at the third 
measurement (26-28 weeks of gestation) in those women who developed early-onset pre-
eclampsia (Table 12). sFlt-1 concentrations were higher at all three timepoints in women who 
developed severe, late-onset pre-eclampsia than in women who developed non-severe, late-
onset pre-eclampsia.
Table 12. Concentrations of soluble vascular endothelial growth factor receptor (sFlt-1) in the 








































Concentrations (geometric mean, 95% confidence interval) of sFlt-1 all four study groups. 
*P < 0.05 compared to late-onset pre-eclampsia, controls with risk factors and without risk factors
sFlt-1/PlGF ratio 
The ratio of sFlt-1/PlGF was higher at 26-28 weeks of gestation in the group of women who
later developed early-onset pre-eclampsia (Table 13). The sFlt-1/PlGF ratio separated women 
who developed early-onset pre-eclampsia from other pre-eclamptics and controls explicitly.  
According to our study, all women who developed early onset pre-eclampsia could be 
identified 4.0 to 6.3 weeks before clinical diagnosis of the disease. 
Table 13. Soluble vascular endothelial factor receptor-1 (sFlt-1) and placental growth factor 















12+0 to 14+0 34.4 (22.2-53.3) 26.6 (21.3-33.2) 24.8 (19.7-30.5) 25.9 (22.3-28.0)
18+0 to 20+0 15.9 (6.6-38.8) 6.7 (5.2-8.7) 6.9 (5.3-8.9) 7.1 (6.1-8.2)








Concentrations (geometric mean, 95% confidence interval) of the sFlt-1/PlGF ratio placental growth 
factor in all four study groups. 
*P < 0.05 compared to late-onset pre-eclampsia, controls with risk factors and without risk factors.
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The role of maternal and placental factors in the risk of superimposed pre-
eclampsia in chronic hypertension (Study V) 
Biomarker data in women with CHT with and without superimposed pre-eclampsia
Plasma syndecan-1 concentrations were lower at 26+0-27+6 weeks (p = 0.03) in women who 
subsequently developed superimposed pre-eclampsia compared to women with CHT without 
superimposed pre-eclampsia. This was not seen at earlier gestational timepoints, nor was 
there any difference over the assessed gestational age range between women with CHT and 
healthy controls.
Plasma PlGF concentrations (across gestation) were lower in women with CHT who 
developed superimposed pre-eclampsia compared to those who did not (p = 0.002) and was 
also discriminatory for superimposed pre-eclampsia at 26+0-27+6 weeks (p < 0.0001).
The ACR was elevated (across gestation) in women with CHT who subsequently developed 
superimposed pre-eclampsia compared with women with CHT (p = 0.007) or healthy controls 
(p = 0.002), and discriminated between women with CHT who did and did not develop 
superimposed pre-eclampsia at 12+0-13+6 and 26+0-27+6 weeks (p = 0.009 and p = 0.006
respectively).
There were no differences in any other marker between women with CHT who did and did 
not develop superimposed pre-eclampsia.
Comparisons between women with CHT without superimposed pre-eclampsia and 
healthy controls
Plasma NGAL and serum cystatin C concentrations were significantly higher across gestation 
in women with CHT without superimposed pre-eclampsia than healthy controls (p < 0.0001 
and p = 0.008 respectively). 
Creatinine clearance was higher across gestation in women with CHT without superimposed 
pre-eclampsia than healthy controls (p = 0.03).
There were no differences in PlGF concentrations between healthy controls and women with 




PlGF concentrations increased with gestation in healthy controls and women with CHT with 
and without superimposed pre-eclampsia (p < 0.0001), except between the second and third 
timepoints in women who subsequently developed superimposed pre-eclampsia (p = 0.70). 
Similarly, the syndecan-1 concentration also increased with gestation in healthy controls and 
women with CHT without superimposed pre-eclampsia (p < 0.01). 
Plasma sialic acid and N-acetyl- -D glucosaminidase (NAG) concentrations also increased 
with gestation (p < 0.0001), but there were no differences between healthy controls and those 
with CHT with and without superimposed pre-eclampsia.
There were no changes with gestation in the ACR in healthy controls or women with CHT 
who developed superimposed pre-eclampsia.
BNP concentrations fell as gestation advanced in women with CHT without superimposed 
pre-eclampsia (p = 0.011) and healthy controls (p = 0.005) but did not decrease with gestation 
in women with subsequent superimposed pre-eclampsia.
There were no changes with gestation in creatinine clearance in women with CHT without 
superimposed pre-eclampsia or healthy controls, but women who developed superimposed 
pre-eclampsia had a significant increase in creatinine clearance at 18+0-19+6 compared to 12+0-
13+6 weeks (p = 0.007) and then lower values at 26+0-27+6 weeks ( p < 0.0001). 
Women with CHT with and without superimposed pre-eclampsia demonstrated a decrease in
plasma symmetric dimethylarginine (SDMA) clearance at 26+0-27+6 compared to 18+0-19+6
weeks’ (p = 0.045 and p = 0.001 respectively), which was not evidenced in healthy controls. 
Cystatin C concentrations increased with gestation in all groups (P<0.0001) with no 
differences between groups.
There were significant increases in the urine NAG:creatinine ratio with gestation in healthy 
control women (p < 0.0001) and women with CHT without superimposed pre-eclampsia (p <
0.0001); the change with gestation was less marked in women with CHT who developed
superimposed pre-eclampsia (26+0-27+6 vs 12+0-13+6 weeks, p = 0.034), but did not 
discriminate between groups. Similarly, the urinary retinol binding protein (RBP):creatinine 
ratio increased with gestation in all groups (p < 0.001), but no differences between subgroups 
were seen.
There were no significant differences between groups or with gestation in plasma ADMA 
concentrations or the SDMA:ADMA ratio.
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Prediction of superimposed pre-eclampsia
The highest observed ROC areas for the prediction of superimposed pre-eclampsia were for 
ACR at 12+0-13+6 weeks 0.87 (95% CI 0.73-1.0) and PlGF at 26+0-27+6 weeks 0.78 (95% CI 
0.55-1.00).
Validation cohort
Samples were taken at 37.1 weeks of gestation (interquartile range (IQR): 32.2, 38.3) for 
women with CHT with superimposed pre-eclampsia, at 34.0 weeks (28.3, 37.3) for women 
without superimposed pre-eclampsia, at 36.2 weeks (34.2, 38.1) for women with pre-
eclampsia without pre-existing disease, and at 37.9 weeks (31.2, 39.2) for healthy controls.
PlGF concentrations were lower in women with superimposed pre-eclampsia than those with 
CHT and/or CKD (p = 0.003), and in women with pre-eclampsia without pre-existing disease 
compared with healthy controls (p < 0.001).
Syndecan-1 was lower with superimposed pre-eclampsia than those with CHT and/or CKD (p 
= 0.001) and after adjustment for gestation remained significantly lower (p = 0.005). 
Syndecan-1 was also lower in healthy controls than women with CHT and/or CKD without 
superimposed pre-eclampsia (p = 0.045) and after adjustment for gestation (p = 0.045). There 
were no differences in syndecan-1 concentrations (p = 0.615) between women with pre-
eclampsia compared with healthy controls even after adjustment for gestation.
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Aspirin in the prevention of pre-eclampsia in high-risk women (Study II)
Of the recruited 947 women with risk factors for pre-eclampsia in the PREDO cohort, 152 
(16.1%) were allocated into the aspirin trial since they had a bilateral second-degree diastolic 
notch in the uterine artery flow examination.  Of the 152 randomised women initially 
recruited into the aspirin trial, 121 were included in the final analysis. The baseline 
characteristics of the 61 women randomly allocated into the aspirin group and 60 women in 
the placebo group are presented in Table 14. Their pregnancy characteristics are presented in 
Table 15.
Table 14. Baseline characteristics of the women in the aspirin trial
Characteristics Aspirin group (n=61) Placebo group (n=60)
Age years (SD) 30.8 (5.3) 31.0 (5.1)
BMI before pregnancy kg/m2 (SD) 27.9 (6.6) 29.7 (7.8)
Primiparous, n (%) 19 (26.2%) 9 (15.0%)
Educational attainment 
Elementary or less 3 (7.8%) 1 (2.4%)
High school or vocational school 7 (17.5%) 15 (35.7%)
Intermediate 13 (32.5%) 13 (31.0%)
University 17 (42.5%) 13 (31.0%)
SD, standard deviation. BMI, body mass index. Continuous data presented as mean (SD).
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Antihypertensive medication, n (%)
Before 20 weeks of gestation 4 (6.6%) 3 (5.0%) 0.8
After 20 weeks of gestation 7 (11.5%) 9 (15.0%)
Weigh gain during pregnancy, kg (SD) 11.7 (4.7) 12.1 (4.9) 0.6
Gestational diabetes, n (%)
Diet 10 (16.4%) 9 (15.0%) 0.6
Insulin 1 (1.6%) 3 (5.0%)
Oral glucose tolerance test performed 6 (9.8%) 5 (8.3%)
Highest systolic blood pressure, mmHg (SD) 142.5 (19.6) 146.2 (21.9) 0.3
Highest diastolic blood pressure, mmHg (SD) 92.1 (11.8) 95.1 (12.5) 0.2
Highest proteinuria, g/day* 3.3 1.3 0.1
Mode of delivery, n (%)
Vaginal 47 (77.0%) 43 (71.7%) 0.8
Elective caesarean section 3 (4.9% 3 (5.0%)
Caesarean section during labour 11 (18.0%) 14 (23.3%)
Apgar score at 5 min 9.0 (0.8) 8.9 (0.8) 0.7
Umbilical artery pH below 7.15, ** n (%) 7 (12.5%) 4 (7.4%) 0.6
Newborn birthweight, g (SD) 3413 (630) 3321 (871) 0.5
Placental weight, g (SD) 602 (131) 585 (150) 0.5
Continuous data presented as mean (standard deviation, SD).
* Geometric mean
** No umbilical artery pH was below 7.00
Of those 31 women who discontinued the study, 4 had a miscarriage (3 in the aspirin group 
and 1 in the placebo group). Eleven women were lost to follow-up or discontinued for various 
nonmedical reasons (7 of these were in the aspirin group and 4 in the placebo group). Five 
women decided to discontinue the aspirin trial because of a medical condition (3 of these 
women were in the placebo group and 2 in the aspirin group). Eleven participants were 
additionally excluded from the analysis because of noncompliance with the study protocol. 
The pregnancy outcome for all of these 31 discontinued women is known. We conducted an 
intention-to-treat analysis, in which we included all randomised women, except the ones who 
miscarried. The results of the intention-to-treat analysis did not differ from the analysis made 
without the excluded women. 
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Primary outcomes in the aspirin trial
Primary outcomes are shown in Table 16. Altogether 19 (15.7%) women were diagnosed with 
pre-eclampsia, 8 in the aspirin group and 11 in the placebo group (RR 0.7, 95% CI 0.3-1.7). 
Sixteen women were diagnosed with gestational hypertension, 10 in the aspirin and 6 in the 
placebo group (RR 1.6, 95% CI 0.6-4.2). The birthweight SD score in the aspirin group 
was  -0.1 (SD = 1.1) and in the placebo group -0.3 (1.3) (P = 0.3). 
Table 16. Study outcomes in aspirin and placebo groups, and relative risk (RR) with 







Pre-eclampsia 8 (13.1%) 11 (18.3%) 0.7 0.3-1.7
Gestational hypertension 10 (16.4%) 6 (10.0%) 1.6 0.6-4.2
Secondary outcomes
Early-onset pre-eclampsia 1 (1.6%) 4 (6.7%) 0.2 0.03-2.1
Preterm pre-eclampsia 3 (4.9%) 5  (8.3%) 0.6 0.2-2.4
Severe pre-eclampsia 3 (4.9%) 8 (13.3%) 0.4 0.1-1.3
Small for gestational age 2 (3.3%) 6 (10.0%) 0.3 0.1-1.6
Severe diagnosis 4 (6.6%) 10 (16.7%) 0.4 0.1-1.2
Early-onset pre-eclampsia = diagnosed before 34+0
Preterm pre-eclampsia = diagnosed before 37+0
Severe pre-eclampsia = b
Small for gestational age = birthweight < -2 SD
Severe diagnosis = early-onser pre-eclampsia and/or severe pre-eclampsia and/or small for 
gestational age 
Secondary outcomes in the aspirin trial
Secondary outcomes are shown in Table 16.  There was one woman with early-onset pre-
eclampsia in the aspirin group and four in the placebo group (RR 0.2, 95% CI 0.03-2.1). 
Severe pre-eclampsia was diagnosed in three women in the aspirin group and eight women in 
the placebo group (RR 0.4, 95% CI 0.1-1.3). In the aspirin group two newborns were 
diagnosed as SGA compared with six in the placebo group (RR 0.3, 95% CI 0.1-1.6). These 
diagnoses were, in part, seen in the same participants. Four women in the aspirin group and 
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ten in the placebo group had one or more of these severe diagnoses (early-onset pre-eclampsia 
and/or severe pre-eclampsia and/or SGA) (RR 0.4, 95% CI 0.1-1.2). Three women in the 
aspirin group and five in the placebo group (RR 0.6, 95% CI 0.2-2.4) developed preterm pre-
eclampsia (diagnosed before 37+0 weeks of gestation). Mean gestational age in the aspirin 
group was 39.1 weeks (SD = 0.8) and in the placebo group 38.9 (SD = 3.0) (P = 0.6). None of 
these differences were statistically significant. One woman in the placebo group had HELPP 
syndrome with early-onset pre-eclampsia. None had eclampsia. 
Among the 795 women with clinical risk factors who were included in the follow-up groups, 
but whose uterine artery Doppler ultrasound waveforms did not fulfil the criteria of the 
aspirin trial, 66 (8.3%) women developed pre-eclampsia, 24 (3.0%) of these were diagnosed 
with severe pre-eclampsia and 16 (2.0%) with early-onset pre-eclampsia. Eighty-nine women 
were diagnosed with gestational hypertension (11.1%). Twenty-four (3.0%) newborns were 
born SGA and ten (1.3%) women both gave birth to an SGA newborn and were diagnosed 
with pre-eclampsia. In the control group of 110 women without known risk factors for pre-
eclampsia, two (1.8%) developed pre-eclampsia. 
Adverse effects
One participant reported sudden deafness in one ear at 24 weeks of gestation. The medication 
was discontinued and her randomisation code was opened: this participant had received
placebo. No other adverse effects were reported.
Results of the meta-analysis
The meta-analysis included two additional studies (246,248). In the meta-analysis aspirin 
started at or before 16 weeks of gestation in women with abnormal uterine artery 
measurements, as an indication of increased risk, aspirin significantly reduced the risk of pre-
eclampsia (RR 0.6, 95% CI 0.37-0.83), and severe pre-eclampsia (RR 0.3, 95% CI 0.11-0.69). 
Aspirin did not reduce the risk of preterm (RR 0.2, 95% CI 0.02-1.26) or term pre-eclampsia 




In our cohort, 10.0% of the women with and 1.8% of the women without known risk factors 
developed pre-eclampsia. Of all pre-eclamptic women, 22.3% had early-onset pre-eclampsia.
The most important risk factors for severe and preterm pre-eclampsia in our cohort were pre-
eclampsia or an SGA newborn in a previous pregnancy, CHT, and type 1 diabetes mellitus. 
Pre-eclampsia in a previous pregnancy was the most important risk factor for term pre-
eclampsia. Obesity increased the risk for term pre-eclampsia and severe pre-eclampsia. Term 
and preterm pre-eclampsia had different risk profiles. The more risk factors a pregnant 
woman had, the stronger her risk of developing pre-eclampsia was. The risk increased 
exponentially as the number of risk factors increased.
We found that pre-eclamptic women had higher circulating FFA concentrations, which,
despite insulin resistance, were suppressed by oral glucose loading. Arachidonic, linoleic, 
oleic and palmitic acids were higher in pre-eclamptic women compared to controls. This may 
have an important role in the endothelial cell dysfunction seen in pre-eclampsia, and may also 
have a role in disturbance of the prostaglandin metabolism, which is associated with pre-
eclampsia. 
In the group of women with CHT, 15% developed superimposed pre-eclampsia.  As an 
implication of endothelial dysfunction and reduced placental angiogenic capacity, these 
women had reduced syndecan-1 and PlGF concentrations and an elevated overnight 
urine:creatine ratio compared to hypertensive women who did not develop pre-eclampsia and 
controls without CHT. No differences between groups appeared in renal tubular or cardiac 
function. Findings of endothelial dysfunction and reduced placental angiogenic capacity are 
likely predisposing factors for superimposed pre-eclampsia in pregnant women with 
hypertension. 
In our cohort, we showed that PlGF can be used in the prediction of early-onset pre-eclampsia 
from the 18th to 20th weeks of gestation and the sFlt-1/PlGF ratio from the 26th to 28th weeks 
of gestation. From 26 weeks of gestation, the sFlt-1/PlGF ratio was able to identify all women 
who later had early-onset pre-eclampsia, without false positives. We also found that serum 
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sFlt-1 is already significantly elevated in the first trimester in women who developed late-
onset, severe pre-eclampsia compared to those who developed late-onset, non-severe pre-
eclampsia.
Our placebo-controlled randomized aspirin trial was limited by a small sample size. Of the 
women who had risk factors for pre-eclampsia, 16.1% were estimated to be high-risk by 
second degree diastolic notches in the uterine artery velocity waveforms and were randomised 
in the aspirin trial. In the placebo group, 18.3% developed pre-eclampsia in comparison to 
13.1% in the medication group. Although both early-onset and severe pre-eclampsia and SGA 
infants were more common in the placebo group than in the low-dose aspirin group, the 
differences between the two study groups were not significant. For the difference to be 
significant, the risk ratio in the early-onset group needed to be 0.12, instead of 0.2. We 
conducted a meta-analysis of similar studies, and according to that, low-dose aspirin started at 
or before the 16th gestational week prevents pre-eclampsia and severe pre-eclampsia, with 
number needed to treat (NNT) 6 and 12, respectively. 
Strengths and limitations of the study
The strengths of the study include the well-characterized study cohorts. In the study of FFA 
profiles (Study I) the case and control groups were relatively homogenous, women with 
gestational diabetes were excluded, and insulin sensitivity was assessed by an intravenous 
glucose tolerance test. The sample size of the study was limited due to the labor-intensive 
design. Moreover, we did not measure FFA in cord blood, which would have added on the 
provided information on FFA metabolism from the fetal side of the placenta. 
The PREDO study cohort used in studies II-V consists of prospectively recruited women with 
risk factors for pre-eclampsia and controls without known risk factors. However, the number 
of women who developed pre-eclampsia was rather small, even though we studied women 
with increased risk of pre-eclampsia. The aspirin trial (Study II) was limited because of the
relatively small sample size. The main reason for that was the use of second-degree uterine 
artery notch as a criterion in selecting women in the medication group. Our objective was to 
distinguish women with the highest risk, however, the number of women who fulfilled this 
inclusion criterion was unexpectedly small, only 16%. Furthermore, the number of women 
who developed pre-eclampsia was also unexpectedly small. The rationale for conducting the 
meta-analysis was to incorporate the findings of our study with the scientific literature despite 
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the small sample size. The high homogeneity for pre-eclampsia and severe pre-eclampsia 
suggested valid findings. 
We initiated the study of vasoactive markers (Study III) at a point when only some of the total 
participants had final outcomes verified by the jury, which limited the available sample size. 
Since we did not collect samples after the 30th week of gestation we were unable to study the 
changes of the biomarkers in women who developed late-onset pre-eclampsia close to the 
established disease. 
For the cluster analysis (Study IV), we had limited information on the onset, severity and 
recurrence of pre-eclampsia in the previous pregnancies. Therefore, we were unable to 
incorporate this information of possible previous pre-eclampsia in estimating the risk. 
In the study of predisposing factors to superimposed pre-eclampsia (Study V), in vivo
assessment of function using cardiac indices, endothelial function and formal measurement of
glomerular filtration would have confirmed the relationship between pre-existing disease and 
the development of superimposed pre-eclampsia.
Interpretation of the study
In the PREDO cohort 10.0% of the women with risk factors for pre-eclampsia developed the 
disease. Of those, 11.6% had early-onset pre-eclampsia and 41.9% had severe disease. Half of 
the women at risk met one or more of the primary or secondary outcome criteria. In contrast, 
from 110 control women without known risk factors for pre-eclampsia, 2 developed pre-
eclampsia (1 had severe and 1 non-severe late-onset pre-eclampsia). Of the control women,
87% did not meet any of the primary or secondary outcome criteria. 
In our study, women who developed early-onset and/or severe pre-eclampsia had different 
risk profiles compared to term pre-eclampsia. CHT was a stronger predictor of early-onset
and severe pre-eclampsia. The results were consistent with earlier studies (249). A pre-
existing endothelial dysfunction that predisposes to placental vascular insufficiency may 
contribute to the development of superimposed pre-eclampsia in CHT. Maternal diabetes-
related vascular and metabolic dysfunction predisposes women with type I diabetes mellitus 
to pre-eclampsia (250). In our cohort, women with type I diabetes mellitus had an increased
risk of severe, early-onset and preterm pre-eclampsia. Klemetti and colleagues (250) reported 
an increased risk for pre-eclampsia in women with diabetes classified as White’s class B to F.
Classes B to F include diabetes which existed before pregnancy to disease with diabetic 
nephropathy. A history of giving birth to an SGA newborn increased a risk of early-onset, 
preterm and severe pre-eclampsia. Conversely, preterm pre-eclampsia in a previous 
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pregnancy has been shown to be associated with having a SGA newborn in a subsequent 
pregnancy without pre-eclampsia (251) which reflects the common placenta-derived 
pathogenesis of these outcomes (252). The outcome is modified by the absence or presence of 
maternal metabolic factors. Previous pre-eclampsia was a strong risk factor for all types of
pre-eclampsia. According to earlier studies, women with early-onset pre-eclampsia have even 
higher risk of recurrent pre-eclampsia than women with late-onset disease (85,253).
Moreover, women with a previous preterm pre-eclampsia have an increased risk of adverse 
pregnancy outcomes in the second pregnancy even in the absence of pre-eclampsia (254). A
previous normal pregnancy is associated with a reduced risk of pre-eclampsia in subsequent 
pregnancy (255). The strongest risk factor for term pre-eclampsia was previous pre-
eclampsia, and accompanied with high BMI, the risk increased. Altogether, the risk for pre-
eclampsia increased exponentially as the number of risk factors increased.
Vasoactive agents in the prediction of pre-eclampsia in the first trimester
Our study of the vasoactive agents was relatively small, however, there are only a few 
comparable studies with prospectively-collected serial samples. We studied PlGF and sFlt-1
at three timepoints (12-14, 18-20 and 26-28 weeks of gestation). We did not show differences 
between early-onset, late-onset and control groups in the first trimester. In larger studies, it 
has been shown that women who develop preterm or term pre-eclampsia already have 
significantly lower concentrations of PlGF in the first trimester (96,256-259). Others have 
demonstrated low first trimester PlGF concentrations only in women who developed early-
onset or preterm preeclampsia (260,261). Recently, in a larger substudy of the PREDO
project (Murtoniemi et al., unpublished), women with subsequent early-onset pre-eclampsia
already had significantly lower PlGF concentration than women who developed late-onset 
pre-eclampia or controls in the first trimester samples. In a recent study by Vieira and 
colleagues (262) low plasma PlGF concentrations in early pregnancy was associated with 
subsequent preterm and term pre-eclampsia in obese women, but only with preterm pre-
eclampsia in non-obese women. However, PlGF concentrations are not sensitive enough to be 
used alone in the prediction of pre-eclampsia in the first trimester. Combined with clinical 
risk factors and physical measurements, PlGF performs well in the early prediction of pre-
eclampsia. Different calculation models have been introduced and some are in commercial 
use. These tests promise significant specificity and sensitivity. These calculation models are 
more sensitive in predicting early-onset and severe pre-eclampsia. The pathology of those 
subgroups is more of placental origin. The group of women with late-onset pre-eclampsia is 
70
more heterogenous, they more often have the maternal type or the non-angiogenic type of pre-
eclampsia without early placental changes and markedly reduced PlGF concentrations.
Vasoactive agents in the prediction of pre-eclampsia in the second and third trimester 
By the 18th to 20th weeks of gestation there were differences in PlGF concentrations between 
those who developed early-onset pre-eclampsia and those who developed late-onset pre-
eclampsia and controls. In all three groups PlGF concentration rose between the first and 
second sampling, however, in the early-onset group PlGF concentration rose less steeply, and 
before the third measurement, the concentration almost halved. In the late-onset group, PlGF 
concentrations rose in the same manner as in the control groups. As with PlGF, in the analysis 
of sFlt-1, similar groups were seen, with significant differences only between the early-onset 
pre-eclampsia group and others. There were only slightly rising concentrations of sFlt-1 in the
longitudinal samples of the other groups, but in the early-onset pre-eclampsia group, the sFlt-
1 concentration rose steeply between the second and third sampling, indicating impending 
clinical disease. This is in line with most other studies (17,258,263). One study found a 
sequential change of sFlt-1 between the first and second trimester to be strongly predictive of 
pre-eclampsia (264).
We were able to identify, four to six weeks prior to the clinical diagnosis of pre-eclampsia, all 
women who developed early-onset disease. A cut-off value of 40 for the sFlt-1/PlGF ratio 
distinctly identified women who developed early-onset from those who developed late-onset
disease. This same finding has been observed by others (97). The sFlt-1/PlGF ratio could be 
used in the follow-up of women at high risk of pre-eclampsia in an asymptomatic stage (97)
and in clinical decision making in women with signs and symptoms of pre-eclampsia (17,265-
268). Stepan and colleagues (97) suggested that in asymptomatic high-risk women with an 
sFlt-1/PlGF ratio under 38, pre-eclampsia could be ruled out for at least a week. Women with 
a ratio between 38-85 are at high risk of developing pre-eclampsia within 4 weeks in an early-
onset setting and should be followed up in 1 to 2 weeks time. In late-onset pre-eclampsia, the 
intermediate result of the ratio (38-110) is suggestive of impending placental dysfunction and 
induction of delivery should be considered. Additionally, the sFlt-1/PlGF ratio may add
valuable information regarding the clinical course and progression of the established pre-
eclampsia. In women with suspected or diagnosed pre-eclampsia, measurement of the sFlt-
1/PlGF ratio can assist in clinical decisions. Again, a ratio under 38 rules out pre-eclampsia 
for at least 1 week. In women with a ratio over 85 in an early-onset situation and over 110 in a 
late-onset situation, a diagnosis of pre-eclampsia or other placenta-related disorder is highly 
probable. In that case, repeated measurements 2-4 days apart would distinguish if the disease 
will progress rapidly, with a steeply rising sFlt-1/PlGF ratio, or if it will be rather stable with 
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ratio not elevating steeply, whereupon a very frequent follow-up is not needed. In the stable 
situation, the authors recommend sFlt-1/PlGF ratio re-measurement in two weeks. A severely 
elevated sFlt-1/PlGF ratio, over 655 in early-onset and over 201 in late-onset pre-eclampsia,
are associated with the need to deliver within 48 hours. 
The PreOS study (269) experimented with the influence of the sFlt-1/PlGF ratio on clinical 
decision-making in more than 200 women with suspected pre-eclampsia. They reported that,
in clinical situations, it influenced the decision making towards appropriate hospitalisation. In
the PreOS study, among women who had suspected pre-eclampsia, only one in five actually 
developed pre-eclampsia. They also reported an increase in pre-eclampsia-related maternal 
and fetal outcomes with increasing sFlt-1/PlGF ratio. Rana and colleagues (270)
prospectively studied 616 women who were evaluated with suspected pre-eclampsia. They 
concluded that of the 167 women presenting with pre-eclamptic symptoms before 34 weeks 
of gestation, the sFlt-1/PlGF ratio significantly improved the prediction of adverse outcomes 
occurring within 2 weeks. From women who had a Flt-1/PlGF ratio over 85, 86.5% delivered 
within 2 weeks, compared with 15.5% of women with ratio under 85. Furthermore, in women
with an atypical pre-eclampsia presentation, with relatively normal blood pressure or no 
proteinuria, this test performed well. The sFlt-1/PlGF ratio was inversely correlated with the 
remaining duration of pregnancy. 
It seems that the sFlt-1/PlGF ratio has the potential to assist in planning the actions in high-
risk women and in women with established pre-eclampsia. However, the different laboratory 
assays may give differing concentrations of sFlt-1 and PlGF, which impacts the cut-off 
values. The threshold values of singleton pregnancies do not work in twin pregnancies (271).
As a clinical implement in the screening of threatening pre-eclampsia, the sFlt-1/PlGF ratio is 
promising and in need of clinical evaluation.
Superimposed pre-eclampsia and the role of endothelial and placental factors
We studied endothelial, cardiac, renal and placental biomarkers in longitudinal samples of 
women with CHT to assess their relative contribution to the development of superimposed 
pre-eclampsia. Few previous studies have explored the influence of pre-existing maternal 
disease on developing superimposed pre-eclampsia (272). In healthy controls and in women 
with CHT without superimposed pre-eclampsia, plasma syndecan-1 and sialic acid 
concentrations increased with gestation. Previously, syndecan-1 protein expression has been 
demonstrated in the placenta, localised to the syncytiotrophoblast interface (273,274).
Elevated plasma concentrations of syndecan-1 in normal pregnancy could reflect placental 
release. However, increased endothelial permeability, evident even in a healthy pregnancy, is 
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suggestive of systemic glycocalyx changes. We found that women who developed 
superimposed pre-eclampsia were characterised by a failure to sustain a normal gestational 
increase in the plasma syndecan-1 concentration, a marker of endothelial glycocalyx function, 
in parallel with the reduction of PlGF. Furthermore, women with CHT or CKD had lower 
plasma syndecan-1 concentrations after diagnosis of superimposed pre-eclampsia compared 
to those without. This may reflect a decline in placental or systemic synthesis of glycocalyx 
constituents and an inability to maintain the protective glycocalyx barrier in those with pre-
existing endothelial injury. Reduced plasma syndecan-1 concentrations may also occur as a 
precursor to the onset and contribute to the clinical manifestations of pre-eclampsia. The 
glycocalyx barrier may become exhausted and thereby contribute to the endothelial 
manifestations. The estimation of glycocalyx function in women with CHT has not been 
previously done. In pregnancy, and particularly in pre-eclamptic compared to healthy women, 
modulators of the glycocalyx, including shear stress, tumour necrosis factor-
oxygen species and matrix metalloproteinases increase (275). We found an increase of NAG
in all groups in our study (Study V), a surrogate biomarker of lysosomal enzyme release, 
including neuraminidase. These lysosomal enzymes are capable of endothelial glycocalyx 
disruption. Syndecan-1 is a natural competitive inhibitor of neuraminidase, hence, a reduction 
in syndecan-1 concentration in those with superimposed pre-eclampsia could lead to further 
glycocalyx destruction. There is also evidence for reduced expression of syndecan-1 by 
trophoblasts in women with pre-eclampsia, which reflects reduced placental synthesis 
(273,276).
Women who developed superimposed pre-eclampsia had lower plasma levels of PlGF 
compared to other groups. This is consistent with earlier findings (277) but not all (278).
PlGF-2 (a splice variant of PlGF) has a potent heparan binding domain (279) which may 
contribute to glycocalyx maintenance and could also contribute to a reduction in syndecan-1
concentration in those who develop pre-eclampsia.  
Microalbuminuria is strongly associated with several factors (e.g., obesity) that are prevalent 
in women with CHT, and endothelial dysfunction is a proposed common mediator. The 
overnight urinary ACR was predictive in hypertensive women who developed pre-eclampsia 
compared to those who did not. This offers an inexpensive way, already in the early 
pregnancy, to evaluate the risk of pre-eclampsia when planning how to monitor the pregnancy 
of a women with CHT. This association between ACR in early pregnancy and later 
developing superimposed pre-eclampsia supports the implication that pre-existing systemic 
endothelial injury plays a role in the development of pre-eclampsia. However, other markers 
of endothelial, cardiac or renal function did not differ significantly between women with CHT 
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who did or who did not develop superimposed pre-eclampsia. Women with CHT without 
superimposed pre-eclampsia had higher glomerular filtration rates estimated by creatinine 
clearance than healthy controls. This may reflect impaired autoregulation. In early 
hypertension, which occurs prior to development of CKD, hyperfiltration is an identified 
feature, which may be the consequence of fewer functional nephrons (280).
Our findings support the hypothesis that pre-existing endothelial dysfunction, assessed by 
overnight ACR, contributes to the development of superimposed pre-eclampsia in women 
with CHT. Reduced shedding of syndecan-1 and decreased PlGF concentrations antedate 
disease development, as well, implicate endothelial glycocalyx disturbance and reduced 
angiogenic capacity in the pathophysiology of pre-eclampsia. 
Free fatty acids 
We found that total concentrations of FFAs were significantly higher in those women who 
were diagnosed with pre-eclampsia than in healthy controls. Of the individual fatty acids, 
arachidonic, linoleic, oleic and palmitic acids were significantly higher in pre-eclamptic 
patients. These high concentrations of FFAs may influence several characteristics of pre-
eclampsia, for example increased insulin resistance, endothelial cell dysfunction and altered 
production of vasoactive substances. 
Most earlier studies have only evaluated total FFA concentrations in pregnant women,
however, individual FFAs have divergent effects. FFA concentrations were already altered 
10-20 weeks before the onset of pre-eclampsia in Lorentzen’s and colleagues study (173,177).
They showed elevated levels of palmitic, oleic and linoleic acids in women who later 
developed pre-eclampsia, as well, as in pre-eclamptic women (177). They also showed that 
there were no differences between early- and late-onset pre-eclampsia groups in FFA 
concentrations. Insulin resistance (20) and increased adrenergic activity (281), characteristics
of pre-eclampsia, are both associated with increased lipolytic activity in adipocytes, which 
possibly underlies the increased circulating levels of FFAs in pre-eclampsia. We did not find 
a relationship between total FFA concentrations and insulin sensitivity, as was expected. In 
pre-eclamptic women, higher insulin sensitivity was associated with higher total FFA 
concentrations. However, this relationship was no longer significant after adjustment for BMI
and gestational age. The interplay between insulin sensitivity and FFAs in pre-eclamptic 
women may be regulated by other factors, for example placental hormones. A comparable 
phenomenon is seen with adipokines, adiponectin and adipocyte fatty acid-binding protein 
(AFABP), which are all elevated in pre-eclamptic women (282,283). In the non-pregnant 
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state, low adiponectin and high AFABP concentrations are associated with insulin resistance
(284) however, in pregnancy they show no relationship with insulin sensitivity (282,283).
FFA and endothelial function
In the non-pregnant state, altered lipid metabolism is a known cause of endothelial 
dysfunction, potential vascular remodelling and atherosclerosis (285). Altogether, an increase 
in plasma glucose, insulin and lipids is associated with endothelial dysfunction (285). An 
increased molar FFA to serum albumin ratio leads to enhanced endothelial cell uptake of 
FFAs and enhanced flux of FFAs into the liver. FFAs are esterified into triglycerides in both 
the endothelial cells and in the liver (286). Consequently, the liver produces increased 
amounts of triglyceride-rich very low density lipoprotein (VLDL) particles into the plasma,
further enhancing the accumulation of triglycerides in the endothelial cells (287). In vitro
exposition of endothelial cells to hyperlipidemic pre-eclamptic sera increases the cellular 
triglyceride content and is accompanied by altered endothelial function (288). The 
accumulation of triglycerides in endothelial cells is a common feature of pre-eclampsia (19)
and may harm endothelial cell function. The mechanisms behind the abnormal elevation of 
triglycerides and FFAs in pre-eclampsia are unknown. One theory proposes that the increased 
insulin resistance, common in pre-eclampsia, results in elevated FFAs and triglycerides by 
increasing fatty acid mobilisation from visceral fat, promoting overproduction of VLDLs by 
the liver, and suppressing postheparin lipoprotein lipase (160,162,289).
FFAs, prostaglandins, and inflammation 
Arachidonic acid, which we found to be increased in pre-eclamptic women, is a precursor of 
vasoactive prostaglandins (prostacyclin and thromboxane). Prostacyclin is produced mainly in 
endothelial cells and is a vasodilator and inhibits platelet aggregation (290). Thromboxane is 
produced mainly in platelets and has vasoconstrictive and platelet aggregatory effects (291).
Pre-eclampsia is characterised by disturbances in the prostacyclin-thromboxane ratio.
Previous studies show that increased arachidonic and linoleic acid in pre-eclamptic women, as 
seen in our study, could lead to a disturbed prostacyclin-thromboxane ratio. High linoleic acid 
concentrations impede the ability of the endothelium to produce prostacyclin and inhibit 
platelet aggregation (292). Endothelial cells exposed in vitro to linoleic acid show a
concentration-dependent reduction in the release of prostacyclin (292). In a study by 
Lorentzen and colleagues reduced prostacyclin release was demonstrated when endothelial 
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cells were treated with sera from pre-eclamptic women (288). The preventative effect of low 
dose aspirin on pre-eclampsia is through its action on prostaglandins. It irreversibly inhibits 
the production of thromboxane by the platelets, but does not affect the production of 
prostacyclin.
An alternative pathway of arachidonic acid metabolism produces lipooxygenase products, 
leukotrienes (293). Leukotrienes could partly be responsible for the inhibition of prostacyclin 
production, hypertension and the increased endothelial permeability seen in pre-eclampsia
(294,295). Leik and Walsh (296) showed that when placental smooth muscle cells are 
exposed to linoleic acid in conditions of oxidative stress, the production of interleukin-8 (IL-
8), a potent inflammatory mediator, is stimulated. Furthermore, the production of IL-8 is 
increased in the placental vascular smooth muscle cells of pre-eclamptic women when 
exposed to linoleic acid (297).
Our samples for FFA analysis were collected at the time of the diagnosis, thus, assumptions 
on the performance of the FFAs in the early prediction of pre-eclampsia can not be made
based on this study.  However, it has been shown by others that elevated serum triglycerides 
and FFAs are already increased before 20 weeks of gestation in women who go on to develop 
pre-eclampsia (173,176). These elevated FFA concentrations return to non-pregnant levels
two to three days after labour in both normal and pre-eclamptic pregnancies (174). FFA 
profiling may be a potential predictive method. With a metabolomics method such as nuclear 
magnetic resonance (NMR) and mass spectrometry, it is possible to measure the distribution 
of lipids in large sets of samples. In future, this may assist in the identification of different 
lipid risk profiles of pre-eclampsia in the early weeks of gestation.
Low dose aspirin in the prevention of pre-eclampsia
Low dose aspirin started in the 12+0 to 13+6 weeks of gestation did not prevent pre-eclampsia 
in our high-risk cohort. In the placebo group, we had more women diagnosed with early-onset
and severe pre-eclampsia, and more SGA newborns, than in the low dose aspirin group, 
however, the differences between groups were not statistically significant. We performed a
meta-analysis of similar aspirin trials. Only two additional placebo-controlled trials with 
women whose uterine artery measurements indicated a high risk had been conducted earlier.
In these studies, low dose aspirin had been started at gestational weeks 12+0 to 16+0.
According to the meta-analysis, women in the low dose aspirin group had a risk ratio of 0.6 
(95% CI 0.4-0.8) for pre-eclampsia and 0.3 (95% CI 0.1-0.7) for severe pre-eclampsia.  
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A wide range of studies on aspirin in the prevention of pre-eclampsia has been published. 
There are considerable differences between these trials and discrepancies in conclusions. 
Studies differ on the weeks of gestation the medication is initiated, the dose, the risk status, 
and on the subgroup analyses. In the earlier trials particularly, low-dose aspirin was started in 
any week of gestation, even when the first symptoms of pre-eclampsia already emerged. At 
present, according to meta-analyses, there is evidence that medication should be started 
before 16+0 weeks of gestation (192,195,298) however, there are contradictory studies 
(190,299,300). There are two active phases of trophoblast invasion during placentation, the 
first of which ends at the 10th week of gestation. The second active phase starts between the 
14th and 15th weeks of gestation and ends around the 18th week of gestation (65,301,302)
however, active endovascular trophoblasts are seen as late as 22th weeks. Aspirin is thought to 
have a positive influence on the development of the placenta when medication is initiated 
well before the end of the second active phase. The current recommendations suggest the 
initiation between 12+0 to 16+0 weeks of gestation (Table 5). It may be speculated whether the 
optimal time of initiation is even earlier. Because all medication in the first trimester of 
gestation, the period of organogenesis, is generally avoided, at this point, this would seem a 
challenging proposal. However, low-dose aspirin is already used in the first weeks of 
gestation, and for example, pre-conceptionally as part of in vitro fertilisation treatments (303-
305). No problems have been reported. One small study of very early-onset aspirin treatment, 
at 8 to 10 weeks of gestation, has been published (306). That included 82 women with aspirin 
treatment and 82 controls. The risk of hypertensive disorders was reduced to 0.07 (95%CI 
0.01-0.5). Meher and colleagues speculated in their recent meta-analysis (299) that aspirin 
should be initiated even after 16 weeks of gestation among high risk women for whom it has 
not yet been initiated. 
The dose of aspirin is important. A wide range, between 50-150 mg per day, is used. Vainio 
and collegues (183) studied the favourable dose of aspirin that inhibits the production of 
vasoconstrictive thromboxane in platelets, but does not affect the production of vasodilatory 
prostacyclin in the vessel wall. They gave 0.5, 1.0 and 2.0 mg/kg/day of aspirin to 
hypertensive and control women and measured major stable metabolites in their urine. They 
concluded that with a daily dose of 0.5-2 mg/kg aspirin, the prostacyclin:thromboxane ratio 
improved. This means that 100 mg of aspirin is appropriate for most pregnant women. In 
speculating on the dose, we should take into account the phenomenon of aspirin resistance 
(307). In patients with cardiovascular disease, the prevalence of aspirin resistance is estimated 
to be significant; according to a meta-analysis, 28% of patients had aspirin resistance (204).
The existence of aspirin resistance should be considered when initiating aspirin treatment to 
high-risk women. Platelet function assays targeted to aspirin-COX pathways may be used to 
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demonstrate platelet function, and compliance to treatment may be determined by measuring 
salicylate levels, however, these have not been assessed in pregnant women (178).
Aspirin trials and meta-analyses can be divided into two types based on the risk status of 
women included. The treatment may be initiated in women who are estimated to belong in a
high-risk group or to a general group of women with an unknown risk status. In large trials or 
meta-analyses on general populations of pregnant women, the effect of aspirin does not seem 
very high (190,300). When limited to an at-risk group of women, the effect is higher
(192,194,195,298,308) as seen also in our meta-analysis (Table 17). However, by 
conventional methods of evaluating the risk status, medical history and physiological 
measurements, the nulliparous women are largely left out of these preventive procedures. By 
determining the risk status with a model of medical history, uterine artery measurements and 
predictive markers in all pregnant women at first ultrasound screening, alongside the trisomy 
screen, low dose aspirin could be offered to women at high risk. 
As our understanding of the pathology of pre-eclampsia has improved, subgroup analyses in
aspirin trials and meta-analyses has become more common. Pre-eclampsia is not one disease, 
but a syndrome with different aetiologies and pathological processes. Pre-eclampsia is 
divided by its onset or time of iatrogenic delivery, severity, existence of vasoactive agents, 
and by estimation of placental or maternal disease. The clinical disease is due to a common 
pathway, endothelial dysfunction. Due to the differences, there might not be one preventative 
medication. It seems that aspirin’s preventative action works most efficiently in the placental/ 
early-onset/severe/angiogenic subgroup. The explanation for this may be regarding aspirin’s 
actions on the placenta via prostacyclin:thromboxane ratio, stimulation of the expression and 
enzymatic activity of HO-1 in endothelial cells (184,185) reduction of ADMA concentration 
(184,185) and dose-dependent inhibition of sFlt-1 production in cytotrophoblasts via COX-1
inhibition (187).
Meta-analysis is a powerful tool in summarising data and increasing the sample size. 
However, there are problems which should be taken into account when planning and 
interpreting results of a meta-analysis (309). There may be bias through the identification and 
selection of studies, quality of the included studies, large degree of heterogeneity of included 
studies, small study effect and publication bias. Due to these problems with meta-analysis 
interpretation, a desire for a large-scale aspirin trial has emerged (310). The ASPRE trial has 
been established to answer the questions left after meta-analyses, and interesting results have














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ASPRE is a prospective randomised controlled trial with a plan to recruit a large number of 
participants (over 30,000) who are screened for pre-eclampsia risk. From the screening, those 
10% of women who were considered in the high-risk group, were randomized to initiate 
aspirin with 150 mg dose per day or placebo, between the 12th to 16th weeks of gestation. 
From the preliminary results, with approximately 800 women in each study group, the risk of 
early-onset pre-eclampsia (before 34 weeks) (unpublished) and preterm pre-eclampsia (before 
37 weeks) (311) were significantly lower in the aspirin group. The reduction of pre-eclampsia 
was reported 80% and 62%, respectively. 
Cost-benefit of low dose aspirin treatment 
The cost-benefit of aspirin treatment has been analysed by Werner and colleagues (312). They 
created a decision model to evaluate four approaches to aspirin prophylaxis in the United 
States in approximately 4 million pregnant women: no prophylaxis, universal prophylaxis, 
ACOG recommendations, and U.S. Preventive Services Task Force (USPSTF)
recommendations (Table 5). They included the costs associated with aspirin, pre-eclampsia, 
preterm birth, and potential aspirin-associated adverse effects and concluded that the USPSTF 
approach was the most cost-beneficial and the second was universal prophylaxis. These 
would reduce morbidity, save lives, and lower health care costs much more effectively than 
the ACOG approach, with markedly tighter limits of aspirin administration. Therefore, this 
outcome supports the recommendation for quite unrestricted use of low dose aspirin when 
using clinical risk factors as the only tool in risk -evaluation.
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FUTURE DIRECTIONS
Further studies in low dose aspirin are needed: 
- The most effective aspirin dose is still undetermined; for example, it is unknown
whether it should be adjusted based on body size. The effect of aspirin resistance
should also be taken into account. 
- There is little information about the long-term influence of aspirin in the child’s 
future health. Longitudinal follow-up of previous and future studies are needed to 
evaluate that. 
Further studies on the prediction of pre-eclampsia:
- First trimester prediction models of pre-eclampsia combined with low dose aspirin
treatment should be tested in clinical work and the impact on morbidity of the women 
and newborns should be studied.
- Studies should examine how the follow-up of at-risk women (determined by sFlt-
1/PlGF ratio measurements in the second trimester) could influence and aid in clinical 
decision making and in the follow-up of women with established pre-eclampsia. 
- New techniques may be introduced in pre-eclampsia prediction from metabolomics 
and proteomics.
- In the future, risk profiling that could individually suggest a specific prophylaxis, for 
example aspirin or a statin, on the basis of the woman’s profile may be possible.
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CONCLUSIONS
In PREDO cohort early-onset and late-onset pre-eclampsia had different risk profiles. Women 
who have had pre-eclampsia in a previous pregnancy, or SGA newborn in a previous 
pregnancy, or who had CHT or type 1 diabetes mellitus were at the highest risk of early-onset 
pre-eclampsia, severe pre-eclampia and preterm pre-eclampsia. Pre-eclampsia in a previous 
pregnancy and a BMI over 30 kg/m2 were the most important risk factors for term pre-
eclampsia. As the number of risk factors increased, the risk of pre-eclampsia increased
exponentially. 
Low serum PlGF predicted early-onset pre-eclampsia from 18 weeks of gestation. There were 
no differences in PlGF in the first trimester samples between the study groups. However, in 
larger studies, in which PlGF is combined with clinical risk factors and physical 
measurements, PlGF performs well in the prediction of pre-eclampsia already in early 
pregnancy.
The sFlt-1/PlGF ratio identified women who went on to develop early-onset pre-eclampsia
weeks before the onset of clinical findings. This may help to plan individual follow-up in 
high-risk women. The sFlt-1/PlGF ratio measurements can also help in the clinical decision 
making among women with signs and symptoms of pre-eclampsia. 
Higher overnight urinary ACR was predictive of superimposed pre-eclampsia in women with 
CHT already in the first trimester. This association between ACR in early pregnancy and
superimposed pre-eclampsia suggests that pre-existing endothelial dysfunction in women with 
CHT contribute to the development of pre-eclampsia. 
Reduced shedding of syndecan-1 and reduce PlGF concentrations antedated disease 
development in women with CHT, implicating the role of endothelial glycocalyx disturbance 
and reduced angiogenic capacity in the pathophysiology of superimposed pre-eclampsia.
Circulating FFA concentrations were higher in pre-eclamptic than in control women. Despite 
insulin resistance, FFAs were suppressed by oral glucose loading. Among individual FFAs, 
arachidonic- and linoleic acid were at the highest concentrations. These may influence several 
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characteristics of pre-eclampsia, for example increased insulin resistance, endothelial cell 
dysfunction and altered production of vasoactive substances. 
We did not show any effect of low dose aspirin on prevention of pre-eclampsia in the PREDO 
study cohort. However, the number of women with pre-eclampsia and, consequently, study 
power were unexpectedly low. In a meta-analysis of studies, that included women with 
abnormal uterine artery measurements and treatment started before 16+0 weeks of gestation, 
low dose aspirin reduced the risk of pre-eclampsia and severe pre-eclampsia. Moreover, 
recent studies by others support the initiation of low dose aspirin before 16+0 weeks of 
gestation in high-risk women. Low dose aspirin reduces the risk of early-onset and severe pre-
eclampsia and, based on current knowledge should be recommended to initiate in high-risk 
women before 16+0 weeks of gestation.
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